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NOMENCLATURE 
 
CGG Cytosine-guanine-guanine, a nucleotide triplet in a strand of    
DNA 
 
FMR-1 Abbreviation for FraX gene (Fragile Mental Retardation 1) 
 
FMRP Protein from the FMR-1 gene that is essential for normal 
functioning of nerve cells. 
 
    FraX > 50 repeats of the CGG nucleotide triplet 
 
FraX   > 200 repeats of the CGG nucleotide triplet 
Full mutation 
 
FraX-FM FraX Full Mutation 
 
FraX-pM FraX Premutation 
 
FraX   60-200 repeats of the CGG nucleotide triplet  
Pre mutation 
 
FRAXA Chromosomal fragile site at Xq27.3 that corresponds to the  
 CGG repeat expansion of the FMR1 gene 
 
FraX Fragile X Syndrome 
 
MR Mental Retardation 
 
m-RNA Messenger Ribonucleic Acid 
 
M-CHAT Modified Checklist for Autism in Toddlers 
 
No Dx No diagnosis 
 
PCR Polymerase Chain Reaction 
 
POF Premature Ovarian Failure 
 
PDD-NOS Pervasive Developmental Disability 
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CHAPTER ONE 
Fragile X Syndrome (FraX) is one of the few disorders affecting child behavior 
for which the exact genetic mutation (FMR-1 gene) is known. FraX is the most 
commonly inherited form of mental retardation and learning disabilities, however, only 
approximately 10% of persons who have this mutation have been identified (Hagerman, 
1997). Therefore, it is imperative to implement enhanced efforts to increase awareness of 
the syndrome and to facilitate earlier detection.  
The gene responsible for FraX, FMR-1, is located on the long arm of 
chromosome X, in the q 27.3 region. The normal size of triple nucleotide Cytosine, 
Guanine, Guanine (CGG) is between 6 to 39 repeats. Depending on the size of the 
expansion, the mutation is categorized into 2 types; the premutation, with an expansion 
between 55 and 200 CGG repeats and the full mutation, with an expansion of more than 
200 repeats (Jin &Warren, 2003). 
One in 250 females and 1 in 500 males carries the FMR-1 gene in a premutation 
state (Turner, Robinson, Wake, Laing, & Partington, 1997). An individual is considered a 
premutation carrier when 50-200 repeats of the Cytosine, Guanine, Guanine (CGG) 
nucleotide base pairs of DNA exist on the X chromosome (Turner et al., 1997). A mother 
has a 50% chance of transmitting FraX to a male or female child because a female 
typically has two X chromosomes on the 23rd pair, which is responsible for determining 
gender. The mother contributes an X chromosome to each child she conceives. On the 
other hand, a male’s 23rd chromosome pair consists of an X and a Y chromosome. 
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Therefore, a man contributes an X chromosome to combine with the woman’s X 
chromosome to reproduce a female. Thus a father who has FraX - premutation, has 100% 
chance of transmitting the FraX - premutation to each of his daughters. On the contrary, 
since a father contributes a Y chromosome to a male child, he has a 0% chance of 
transmitting FraX to a son.  
Females are also affected with the actual syndrome (full-mutation - greater than 
200 repeats of the (CGG) trinucleotide base pair), but usually less severely and less 
frequently (Hagerman et al., 1992). FraX occurs relatively equitably in all racial and 
ethnic groups (Crawford et al., 1999). It is a condition of major epidemiological 
importance among mentally handicapped males and “must be considered in the 
differential diagnoses of a child with developmental delay, mental retardation, or learning 
disability” (Pimentel, 1999, p. 639). 
Not only does the prevalence of FraX necessitate focus on diagnosis and 
therapeutic interventions, but also the emerging data regarding atypical transmission and 
phenotypic expression warrants close focus on this syndrome (Shapiro, 1997; Sherman, 
Jacobs, & Morton, 1985). The genetic expression of FraX is atypical in that some female 
carriers may have clinical symptoms of the disorder and some males who inherited the 
gene may not be affected clinically (Braat, Smits, & Thomas, 1999; Franke et al., 1996; 
Franke et al., 1999; Hagerman et al., 1992; Schwartz et al., 1994; Sherman et al., 1985). 
This phenomenon is of significance, especially in light of the increased number of 
individuals who may possibly experience behavioral or physiological maladies because 
of being a premutation-state carrier of the FMR-1 gene (Dorn, Mazzocco, & Hagerman, 
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1994; Franke et al., 1996; Franke et al., 1999; Johnston et al., 2001), thus complicating 
early diagnosis and intervention. 
Additionally, identifying infants and toddlers with FraX is challenging, because 
many of the unique behavioral symptoms are not obvious until the child is18 to 24 
months of age (Hagerman, 2002). The principal investigator developed the 
Biopsychosocial Screening Inventory for Fragile X Syndrome (BIPSSI - FX), which is a 
parent survey to screen very young children in clinical and non-clinical settings. The 
BIPSSI - FX includes a Biological Parent Subscale that facilitates identification of the 
child. Questions in the BIPSSI - FX identify parents at risk for the FMR-1 gene mutation. 
It is anticipated that the inclusion in the BIPSSI - FX of characteristics identified 
repeatedly in research studies (Franke et al., 1999; Lesniak-Karpiak, Mazzocco, & Ross 
2003) of intellectually normal carriers, such as premature ovarian failure, depression, 
anxiety and obsessive-compulsive behaviors, will facilitate identification of carriers as 
well as accurate detection of FMR-1 gene mutation (the gene that causes FraX) “at risk” 
status in young children. 
Problem Statement 
The early identification of children affected with FraX is important because 
interventions exist that may decrease symptoms (Grandin, 1992; Sallee et al., 1998; 
Scharfenaker & Stackhouse, 1995; Zisserman, 1992) and research concerning treatment 
and corrective interventions is increasing (Berry-Kravis, 2004; Chiurazzi et al., 1998; 
Neri, Pomponi, Pietrobono, & Chiurazzi, 2001;Rattazzi, LaFauci, & Brown, 2004; 
Torrioli et al., 1999). Former United States legislator Wes Watkins and other members of 
Congress, have emphasized the responsibility of researchers and practitioners to "learn, 
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teach, and promote awareness of the incidence, causes, symptoms, effects, and treatment 
of Fragile X, and support screening for Fragile X to permit early intervention and 
treatment" (Watkins, 2000, p. 1). 
Identification of individuals who have the mutated FMR-1 gene will facilitate 
their participation in effective technology, research, and educational and behavioral 
strategies. Early identification and intervention is especially crucial, since timely 
identification and intervention facilitate a higher quality of life and the possibility of 
these individuals to be gainfully employed members of communities. The financial 
burden of care may be decreased from the estimated $1 million to $4 million range spent 
over a lifetime to provide care for an individual who has FraX (Finucane, 1996). 
Currently there are no reliable and valid psychometric measures to screen for FMR-1 
gene “at-risk status” in infants and toddlers (Bailey, 2004). 
Purpose 
The study proposed to test the validity and reliability of an instrument, the 
BIPSSI-FX devised to screen very young children and their parents for “at-risk status” for 
the FMR-1 gene. The principal investigator designed the tool to screen toddlers, 
preschoolers and, school age children using parent reports.  
Objectives 
The goal of the study was to test the reliability and validity of the BIPSSI - FX in 
detecting FMR-1 gene mutation in young children. The objectives of this study were to 
explore the efficacy of the BIPSSI - FX to differentiate between children who have  
FMR-1 gene mutation and those who do not. 
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Significance 
Timely identification of young children who have social or emotional challenges 
is strongly emphasized by child development specialists (Bailey, Skinner, & Sparkman, 
2003). A method of screening young children is crucial to their well-being (Bailey et al., 
2002; Squires et al., 1999). Young children’s emotional and social problems are often 
overlooked until the problems have reached serious magnitudes. Screening young 
children for FraX may empower parents, as front line screeners, to seek an early 
diagnosis and consequently implement effective early intervention for the child who is at 
risk for developmental delays or disabilities. 
Assumptions 
The assumptions underlying this study emanate from the presuppositions of 
biopsychosocial frameworks of human development, literature regarding Internet studies, 
and a perusal of primary caregiver comments available on listserv groups for parents of 
children with FraX, autism, and Down Syndrome (Trisomy 21). The assumptions of this 
study are: 
1. The unique complexities of Fragile X Syndrome may be differentiated 
from those of other syndromes and disorders. 
2. Family composition and interaction partly determine the manifestations of 
physical, cognitive, and social behavior and biological development of 
young children with the FMR-1 gene mutation. 
3. Primary caregivers who invest in completing online surveys, without 
compensation, provide valid and reliable information regarding their 
child’s development. 
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The principal investigator reviews the pertinent theories and existing screening 
tools for FraX and discusses the development of the BIPSSI-FX in Chapter Two. Chapter 
Three provides a detailed account of the methods including the statistical tests of the 
study. A summary of the data analysis plan and the results, including tables and figures 
are presented in Chapter Four. Finally, discussion of the research findings including 
interpretations, limitations, and recommendations is presented in Chapter Five. 
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CHAPTER TWO 
REVIEW OF THE LITERATURE 
Theoretical Framework 
An investigation of the development of young children who are at risk for the 
FMR-1 gene mutation necessitates the use of a conceptual framework. Discoveries of 
exact genetic markers of various disorders resulting from the “Human Genome Project” 
and the current federal government emphasis upon funding biological and genetic based 
research have impelled researchers from many disciplines to embark upon biosocial-
focused studies. Although reluctance to incorporate a biosocial approach to human 
development and family science remains in some disciplines, leaders in the various 
disciplines are emphasizing the necessity of incorporating biological variables (Bailey, 
Hebbeler, Scarborough, Spiker, & Mallik, 2004; Grove, 1995; Udry, 1995). The use of a 
conceptual framework of sufficient complexity is paramount as multi-disciplinary 
researchers play key roles in research, practice, and policy, which influence early human 
development. Hence, the premise upon which the BIPSSI-FX is developed is the 
imperativeness of a careful consideration of the multifaceted dimensions of human 
development. The theoretical framework for the study is adapted from biosocial 
(Gottlieb, Walshten, & Lickliter, 1998; Kandel & Squire, 2000) and systems perspectives 
of human development. The complexity involved in describing the relationship of 
multiple factors related to FraX needs the clarity and structure that an ecological model 
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affords, but in a dynamic and contextual manner provided by biopsychosocial 
frameworks. 
Society’s focus on health promotion, wholism, and the ability to control 
phenomena in conjunction with the existence of federal research funding for integrative 
approaches to complex problems have spawned an increase in studies in which biosocial 
entities are addressed (Williams & Lessick, 1996). According to Lerner (1998), humans 
are composed of a biological genotype and a sociological genotype. Lerner (1998) 
cleverly uses the oxymoron "sociological genotype" to emphasize hereditary influences 
on humans’ behavior in society and “biological genotype” to emphasize the multi-
systemic role of genes on the individual, which in turn affects the person’s interactions in 
society. Because of the massive quantity of genes, the likelihood of two people having 
completely the same genes is virtually impossible. Thus, diversity in studying the role of 
context and time merits full consideration, as well as the similarities and differences in 
human development and their influence on society. The framing premise of this study is 
the unique social interactions of children with FraX. Furthermore, assessment of these 
interaction patterns may facilitate identification of a child’s risk for the FraX genotype, 
which predisposes an individual for atypical and often challenging interactions in society. 
Gottlieb’s (2002) Probabilistic Epigenetic Biopsychosocial Conceptual 
Framework of Development includes four major aspects of human development from a 
contemporary, dynamic, and contextual perspective (Lerner, 1998). Furthermore, of 
crucial importance to early human development is that Gottlieb (2002) and other 
contemporary theorists, such as Lerner (1998), Overton (1998), and Thelen and Smith 
(1998), define development as change, which occurs over time, and is constant. 
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Gottlieb (2002) further emphasizes that the multiple levels of development – 
genetic, neural, behavioral, and environmental – have equal importance; no one level 
holds greater value than the other does. The levels are multidirectional and inextricably 
fused, fusion being the process by which the levels of development interact 
simultaneously (Tobach & Greenberg, 1984). Specifically, the genetic and behavioral 
levels of Gottlieb’s model are the key concepts of this research study. The genetic level 
of Gottlieb’s model includes the basic biological components of human development, 
which are deoxyribonucleic acid (DNA) – the basic molecule of inheritance. Genetic 
instructions are encoded in base pairs. Gottlieb next considers the role of ribonucleic acid 
(RNA) molecules, which function to build proteins. Comparison is made between the 
FMR-1 gene and the behavioral level of development. The genetic and the behavioral 
levels are specifically addressed in this research study, although a comprehension of the 
interaction of each of the levels is important. 
In contrast to an organismic worldview of predetermined epigenesis, Gottlieb 
(2002), terms the process of human development, probabilistic epigenesis. In other 
words, a general anticipated order occurs in the development of the young human, but 
this order is not concrete, but is probabilistically altered by the interactions of numerous 
variables. The current dissertation research compares children with different genetic 
causes of retardation, for example, Down Syndrome (Trisomy 21), with FraX. Although 
the starting point and pathway for both of these groups of children differ, the typical 
result is the same: developmental challenges or retardation. This process of differing 
starting points or pathways and the same endpoint is termed equifinality (Gottlieb et al., 
1998). 
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The importance of equifinality for FraX is best observed by comparing synaptic 
pruning in children with FraX, Down Syndrome (Trisomy 21), and no genetic 
abnormalities. Children without genetic abnormalities undergo a pruning of unused 
neural pathways, which facilitates neural communication (Greenough et al., 2001; 
Grossman et al., 2003; Kandel & Squire, 2000; O’Donnell & Warren, 2002) Researchers 
and theorists believe that children with Down Syndrome (Trisomy 21) undergo 
overpruning during synaptic development in the early years, whereas children with FraX 
experience underpruning (Johnston, 2004). Researchers posit that the role of 
environmental experience and early intervention in the reduction of over - and 
underpruning is extremely important, although it has not been definitively researched 
(Churchill et al., 2002; Grossman et al., 2003; Hessl et al., 2001; Kates et al., 2002; 
O’Donnell & Warren, 2002). The differentiation of these groups of children by under- 
versus overpruning suggests that the groups should also differ behaviorally and provides 
a key rationale for the current dissertation research. 
Family stress models, systems theories, and ecological theories are commonly 
used as organizing frameworks for human development and family science studies. 
However, neither systems theories nor family stress theories explicitly make allowance 
for proximal causation from a biological or genetic perspective. Each of these models has 
attributes that may be effectively used to interpret aspects of the phenotypic expressions 
of individuals with FMR-1 gene mutation and of their families. Thus, FraX is defined by 
the occurrence of changes to the FMR-1 gene. The molecular changes (FMR-1 gene) 
impact the action of messenger riboneucleic acid (m-RNA), which consequently 
influences the production of a key protein - the Fragile X Mental Retardation Protein 
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(FMRP), which is believed to be essential for normal nerve function (Greenough et al., 
2001; R. J., Hagerman et al., 2004; Hagerman, 1996b; Jacquemont et al., 2004; Mittal & 
Pandey, 2002; Warren & Nelson, 1994). The absence of normal nerve functions affects 
various systems of the body. While the behaviors of the child affected with FraX often 
holistically impact the primary caregivers, siblings, extended family, conversely each of 
these entities affects each level of the child’s development. Although each of these 
concepts and the variables, which measure them, are important in research on FraX, the 
current dissertation research project focuses only on the behaviors of young children that 
discriminate those with FraX from those with other developmental delays or diagnosed 
disabilities. 
Review of the Literature 
Significance 
Gaining increased attention is the identification of genetic and other biochemical 
etiologies of learning disabilities, mental retardation and psychoneurological disorders 
such as schizophrenia, autism, depression, attention deficit disorder, and anxiety 
disorders (Williams & Lessick, 1996). The Human Genome Project (HGP), a 
collaborative international project initiated in 1990 whose goals were to identify and 
sequence the entire human genome, fueled this fervor with the rapid identification of the 
genetic basis of disorders that affect behavior such as FraX (Williams & Lessick, 1996). 
In fact, the identification of the FMR-1 gene, in 1991 was one of the first major findings 
of the HGP (Williams & Lessick, 1996). Moreover, the attention of funding agencies, 
society, and researchers focuses upon unveiling genetic causes of developmental, 
behavioral, and learning disorders. FraX, the most commonly inherited form of mental 
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retardation (Sutherland, Mulley, & Richards, 1993; Shapiro, 1997), is one of the few 
disorders affecting child behavior for which the exact genetic sequence is identified. 
Incidence of males is estimated to range from one in 1500 (Sherman, 1991) to 1 in 4000 
(Turner, Webb, Wake & Robinson, 1996). Females are also affected by FraX, but less 
severely and at a lower incidence. Crawford, Acuña, and Sherman (2001) present a meta-
analytic review of epidemiological studies of FMR-1 and the FraX, in which studies from 
various countries have estimated the prevalence of the full mutation and the premutation. 
However, most of the populations studied remain Caucasian, with little information about 
other racial groups. Crawford et al. (2001), estimate the full mutation to range from one 
in every 3,717 to 1 in every 8,918 Caucasian males in the general population. In the 
premutation, prevalence estimates range from one in every 246 to 1 in every 468 
Caucasian females in the general population. For Caucasian males, the prevalence of the 
premutation is estimated to be one in every 1,000. Pembrey, Barnicoat, Bobrow, Turner, 
& Carmichael (2001), assessment of screening strategies of FraX in the United Kingdom 
found similar prevalence rates as those reported by Crawford and colleagues, for the full 
mutation and the premutation.  
Screening in Young Children 
Child development specialists strongly emphasize the importance of timely and 
accurate identification of young children who demonstrate developmental delays or social 
or emotional challenges. The importance of screening instruments to accurately identify 
young children is crucial to their well-being (Bailey et al., 2002; Squires et al., 1999). 
Few psychometric instruments are currently present to facilitate identification of children 
younger than 18 – 24 months of age who may be “at risk” for the FraX (Bailey et al., 
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2002). Because of this deficit, many of the emotional and social problems of young 
children are overlooked until the problems have reached serious magnitudes (Bailey et 
al., 2002; Squires et al., 2001). Additionally, major interventions are more efficacious 
when implemented early in the child’s life. Most children are not formally diagnosed as 
having social or emotional difficulties until school age or approximately 5.2 years. 
Moreover, identification for special education does not occur until the child is 
approximately 8 years of age (Forness, Kavale, McMillian, Asarnow, & Duncan, 1996). 
Furthermore, Forness, and colleagues (1996) found that formal placement in a program 
for children with social-emotional challenges typically does not occur until 
approximately the age of 10 years old, thus possibly missing crucial early intervention, 
which may impede the child achieving his or potential. In addition to early identification 
of social and emotional challenges, a multi-system assessment, which includes 
developmental, cognitive, physical, and familial assessments, is crucial to effectively 
screen toddlers for FraX.  
Overview of Screening Checklists for FraX 
Since the exact gene mutation that causes FraX was discovered as a result of the 
International Human Genome Project, screening studies to facilitate referrals for FMR-1 
gene diagnostic tests have proliferated.  
The eight checklists reviewed in Table 1 are all meant to facilitate the detection of 
critical clinical attributes of the genotype that causes FraX, thus providing reliable 
indicators of individuals who should be referred for diagnostic testing of FMR-1 gene 
changes. Research design and sampling vary across the studies, in that some only 
involved professional appraisals or review of clinical records and others also incorporated 
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parent interviews. Each of those studies emphasizes the cost-effectiveness of using 
screening checklists to avoid unnecessary costly genetic testing. Note that Bailey et al. 
(2001b) estimate the costs of DNA testing to range from $200 to $400. In contrast, 
checklists may be incorporated into routine clinical examinations. 
Older screening tools focused heavily on physical characteristics such as 
macroorchidism (enlarged testicles), elongated face, elongated and/or protruding ears, 
simian creases ( a single crease across the palms) in the palms, hyper extensible finger 
joints, highly arched palate, broad forehead, flat feet, soft velvety skin, and callused 
hands (Hagerman, 1991). As is depicted by Table 1, screening tools mostly focus on 
social, behavioral, and emotional attributes (Bailey et al., 2001). All tools address gaze 
avoidance or avoidance of eye contact. Additionally, anxious, nervous, or hyperactive 
behaviors have been included in each of the instruments, and, self-injurious and /or 
repetitive behaviors are assessed. 
Only three checklists (Bailey et al., 2001b; Giangreco, Steele, Aston, Cummins, 
& Wenger, 1996; and Reiss et al., 1992) assess cognitive functioning of the individual, 
although most males with FraX have moderate mental retardation and delayed attainment 
of developmental milestones. Furthermore, only Bailey et al., (2001b) addressed 
developmental indices. Family history of mental retardation however, is a common 
thread in checklists for FraX. With the exception of three tools (Maes, Fryns, Ghesquire, 
& Borghgraef, 2000; Teisl, Reiss, & Mazzocco, 1999; Reiss et al., 1992), all tools 
reviewed inquire about a family history of mental retardation. However, no 
characteristics associated either empirically or anecdotally with premutation carriers of 
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the FMR-1 gene were included on any other tools, except for “maternal female with 
psychiatric disorder” (Giangreco et al., 1996, p. 612).  
Bailey and colleagues (2001b) emphasized the importance of assessing 
development in infants and toddlers suspected as “at risk” for FraX, and proposed a 
checklist inclusive of characteristics discriminating typical infant and toddler behaviors 
from those indicative of autistic behaviors. This proposed checklist includes items from 
the Checklist for Autism in Toddlers (CHAT). Furthermore, the checklist proposed by 
Bailey and colleagues contributes promising new ideas, in that none of the existing tools 
includes developmental indices.   
Another missing area in existing checklists for FraX is phenotypic characteristics 
of the child’s biological family other than mental retardation. Numerous research studies 
(Allingham-Hawkins et al., 1999; Franke et al., 1996; Murray et al., 2000) address 
characteristics associated with premutation carriers at a significantly higher rate than in 
the general population, such as premature ovarian failure, ovarian cysts, depression, 
anxiety, or obsessive and compulsive behaviors. In contrast, none of the existing tools 
specifically addresses emotional and behavioral functions or biological characteristics of 
the birth parents, siblings, and extended family. This omission may substantially impact 
the specificity and sensitivity of the screening tool to detect young children who may be 
at risk for FraX. 
Review of Existing Checklist Screening Tools for FraX 
Although some of the studies involving aforementioned screening checklists for 
FraX have yielded sensitivity and specificity data, none has been replicated. Bailey and 
colleagues’ (2001) proposed checklist has not yet been applied to a research study. 
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Therefore, no data regarding efficacy are available. However, several items included in 
the developmental subscale were adapted from the widely used Baron-Cohen, Allen, and 
Gillberg (1992) Checklist for Autism in Toddlers (CHAT). 
Similar to Bailey and colleagues (2001), Lachiewicz, Dawson, and Spiridigliozzi, 
(2000) found deficits in the existing clinical checklists for assessing FraX “at risk” status 
in young children and proposed a checklist for FraX. The proposed checklist was based 
upon the outcomes of a study of comparative symptoms involving a group of 36 boys 
with FraX and 37 boys with developmental disabilities for whom FraX had been ruled-
out. The groups of boys (ages 2.2 years to 10.2 years, with a mean age of 6.1 years) were 
matched for age. Four of the 42 clinical characteristics of young boys with FraX (hallucal 
crease, adverse response to touch on the skin, difficulty touching tongue to lips, and 
elongated face) were present significantly (p < .0012) more in the boys who had FraX 
than in boys with other developmental disabilities. Additionally, predictive trends were 
seen for the following ten characteristics: elongated face, family history of disabilities 
(including FraX, autism, mental retardation and learning disabilities), ear length greater 
than the 75th percentile, hyperextensible joints, hand calluses, brisk deep tendon reflexes, 
gaze avoidance/poor eye contact, difficulty moving the extended tongue from side to 
side, testicular volume > mean for age, and previous diagnosis of mental retardation. The 
clinical characteristics described in more than 80% of the group of boys with FraX were 
soft skin over the dorsum of the hand and hyperextensible metacarpophalangeal 
joints(100%), medical history of more than five ear infections (97%), highly arched 
palate (94%), previous diagnosis of mental retardation (91%), difficulty pronouncing 
“linoleum” (86%), hallucal crease (83%), elongated face (83%), gaze avoidance/poor eye 
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contact (83%), and head circumference greater than the 50th percentile (81%). Lachiewicz 
et al. (2000) proposed a 25-item, four-subscale (behavioral items, past medical history, 
physical characteristics and oral-motor/language characteristics) clinical checklist to alert 
professionals to boys who may be positive for the FMR-1 gene mutation, based upon the 
outcomes of their study and the data from other studies. However, an exhaustive review 
of the literature has not identified any studies in which the proposed checklist has been 
used. Therefore, reliability and validity data for the proposed checklist as a whole are not 
available. 
FraX more frequently and more severely affects males than females; therefore, 
many of the clinical screening checklists have limited their application to males. In 
keeping with this trend, Maes et al. (2000), tested the 28-item (7 physical characteristics 
and 21 behavioral traits) phenotypic checklist they developed by comparing a group of 
110 boys and men diagnosed with FraX on the basis of both chromosomal and molecular 
(DNA) analyses with 79 members of the same gender who had mental retardation of 
unknown causes (FraX and other genetic or chromosomal disorders having been ruled 
out). The two groups were matched for cognitive age, cognitive level of development, 
and social adaptation. The scores derived from the checklist of boys seventeen years of 
age and younger were analyzed both separately from those of the adult participants and 
were analyzed conjointly. The version of the checklist used in the study conducted by 
Maes et al. was a revision of an original 69-item checklist, and it included only the 28 
items, which were significantly more frequent in boys and men with FraX compared to 
those negative for FMR-1 gene changes during a preliminary study. This final checklist 
was designed to meet the following criteria:  “1) easy to use and score, 2) contain 
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relevant items, 3) amenable to scoring in a clinical setting on the basis of direct 
observation, and 4) items clearly defined to ensure a high level of interrater reliability” 
(Maes et al., 2000, p. 209). Additionally, demographic data were collected to facilitate 
accurate interpretation of the results of the checklist. The results from a study in which 
the tool was used are reported in the following paragraphs.  
Maes et al., (2000) designed the checklist to be administered by “any person 
having medical or psychological-educational qualifications…” (p. 210). Concrete and 
observable characteristics or examples were provided to facilitate scoring for each of the 
28 binomial (yes/no) items. In Maes et al.’s opinion, referral to a physician or genetic 
counselor is recommended for individuals who score 17 to 25 and a score of 26 or higher 
makes such a referral essential. The level of the scoring is adjusted in cases in which 
there are numerous instances of, “not applicable,” such as in situations in which a child 
cannot yet speak. Note that while the checklist is designed to facilitate appropriate 
referrals, it is not considered as diagnostic.  
Linear regression analysis was used in the study conducted by Maes et al. (2000) 
to examine the items that contributed most to the checklist’s discrimination of individuals 
with FraX from others. The following items revealed the greatest ability to discriminate 
FraX from other developmental disabilities: large protruding ears, macroorchidism, 
fearfulness, and hand biting. Hyperextensibility of joints and the following behavioral 
features demonstrated moderate to low discriminatory ability:  hyperactivity, impulsivity, 
hypersensitivity to changes, gaiety/cheerfulness, avoiding eye contact, and echolalia. The 
predictability of FraX risk status to checklist score showed that a weighted score (derived 
using coefficients based on parameters of predictability of FraX with weighted scores 
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ranging from <17 to >29) of <17 yielded 0% risk of having FraX, a score of 17 to 25 
yielded a 23.5% risk, a score of 26-29 yielded an 82 % risk of having FraX, and a score > 
29 was indicative of FraX (100% chance). 
Cronbach’s alpha, used to test the internal consistency of the checklist, was .84 
for the total list, .74 for the physical items, and .82 for the behavioral features. The 
validity of the checklist, measured by one-way Analysis of Variance (ANOVA), revealed a 
significant difference between the FraX positive group and the FraX negative group on 
both the physical and the behavioral items, F (1, 128) = 89.77, p<.0001 and F(1, 187) = 
45.96, p< .0001 respectively. Likewise, the FraX positive group scored significantly 
higher on the total checklist, F (1, 128) = 79.03, p<.0001. An analysis of the effect of age 
on validity revealed that the checklist had the greatest level of validity for the 6-12 year 
age group and the lowest level of validity with regards to behavioral features for adults 
over 50 years of age. 
The sensitivity of the Maes et al. (2000) checklist, measured by the number of 
individuals with a diagnosis of FraX, who were correctly identified, was 93%. However, 
7% of those who actually had FraX were missed (false-negatives). The percentage of 
correctly identified control group members (the specificity), was 92.3%, but the checklist 
incorrectly detected 7.3% of the group as being at risk for FraX (false-positives). 
Lowering the criterion for referrals for diagnostic testing to score of 17 and above would 
eliminate all of the false negatives, thus increasing the sensitivity of the tool to 100%, but 
the specificity of the checklist would decrease to 42.5%, thereby falsely identifying more 
than half of the control group as  “at risk” for FraX. Therefore, the researchers categorize 
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a score of 17-25 as “referral recommended” and label a score of 26 or higher as “referral 
for diagnostic testing required” (p. 211).    
The Sensitized Affected State Consensus Group Screening Tool (Teisl et al., 
1999) is the only study of the eight reviewed (see Table 1), in which females were 
included in the sample. The inclusion of females is congruent with the goal of the present 
dissertation research project:  to develop a screening tool in which higher functioning 
children with the mutated FMR-1 gene may be reliably identified. The authors clearly 
explained the necessity of a tool in which the more subjective behavioral phenotypic 
expressions might be captured, so that a screening tool may identify the higher 
intellectually functioning children with FraX, as well as those who demonstrate greater 
cognitive impairment. 
Parents of 55 preschool and school-aged children positive for the FMR-1 gene 
full-mutation completed a brief 11-item screening questionnaire. Each of the 55 children 
in the FMR1 positive group was matched for gender, age, and IQ with a child in a pool of 
1600 children with learning disabilities or delays of unspecified etiology. The parents of 
the comparison group also completed the 11-item questionnaire. The questionnaire was 
truncated to include only the following items, for which highly significant (p<.01) or 
significant (p<.05) group differences occurred and on which the FMR-1 positive group 
scored at least 15% higher than the control group:  “taken medication,” “avoids eye 
contact,” “nervousness/anxiety,” “repetitive movement,” “repetitive word/phrase” and 
“injured-self. 
A total score, calculated on a 6-point scale having 1 point for each positive 
endorsement, was assigned to each of the 110 participants. Seventy percent of the 
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preschoolers with FraX received scores > 3, whereas only 26% of the control group 
received a score this high. All of the preschool children who received a score of ≥ 5 had 
FraX, which means that the specificity and sensitivity of the tool was perfect at this score 
for the preschoolers. In contrast, this impressive level of specificity or sensitivity was not 
present in the school-age group. Additionally, when the data were analyzed by gender, 
the specificity of the tool decreased, thus necessitating false-positives to facilitate 
effective screening for females. 
Three similar studies, conducted by Hagerman, Amiri, & Cronister (1991), 
Giangreco, and colleagues (1996), and deVries, et al. (1997) tested the efficacy of a 
checklist to correctly detect a need for DNA analysis for the FMR-1 gene. Each had a 
goal of eliminating unnecessary testing without risking failure to test individuals who are 
indeed positive for FraX. Each study used the results genetic testing for FraX as the 
criterion reference for the brief phenotypic checklists. 
Hagerman et al.(1991) reported the findings of a prospective screening of 107 
males with mental retardation or severe learning disabilities, ages 1 years to 58 years, in 
which the 13-item Fragile X Checklist (Hagerman, 1987), was used. The purpose of the 
study was to utilize a checklist in which a family history of mental retardation, physical 
traits, and behavioral characteristics typical of FraX were assessed to facilitate 
identification of prepubertal boys who are at risk for having FraX. The Fragile X 
Checklist is a modification of a screening checklist developed by Rimland (1984). 
The completion of the checklist involved a physical examination of the participant 
and interview with the parent or guardian. If an item was scored as “not present,” 
“borderline or present in the past,” “definitely present” these descriptors were quantified 
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as 0, 1, or 2, respectively. Measurement standards were implemented to facilitate 
reliability. For example, hyperextensibility of the metacarpal phalangeal joints was 
measured as extension greater than or equal to 90° when digits 2 through 5 were 
dorsiflexed while the palm was flat on a table. Furthermore large testicles were quantified 
as greater than two standard deviations in volume for age or greater than 30 ml in volume 
for adults. Additionally, hand biting was defined to include the biting of the wrist and 
hand but not nail biting. Tactile defensiveness was measured as an aversion to touch or 
other tactile stimuli that are not typically bothersome to others. No descriptors were 
provided for hyperactivity, short attention span, and perseverative speech. However, a 
family history of mental retardation was defined as any relative in up to three 
generations, on either side of the family, and was scored as “2.” This item was further 
clarified by quantifying a relative described as slow or probably retarded, but for whom 
there was no corroborative cognitive testing, as “borderline” (score 1). Hagerman et al. 
(1991) compared the mean total scores for the patients who were positive for FraX with 
those who were FraX negative. The two groups were significantly different (t- test, p 
<.001). Additionally, Chi-square analysis revealed perseverative speech, large or 
prominent ears, and large testicles, as seen significantly (p<.005) more frequently in 
patients positive for FraX. Tactile defensiveness, poor-eye contact, and a family history 
of mental retardation, were significant at the p < .05 level. Step-wise logistic regression 
analysis was used to determine which items were most useful in predicting membership 
to the FraX positive subgroup. This analysis, conducted for the 78 patients for whom 
there were no missing data, revealed that large testicles and tactile defensiveness were the 
best independent predictors of membership in the FraX group.   
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Later, Giangreco et al. (1996) retrospectively analyzed clinical characteristics 
from the records over a 2 year period of time, of 273 males and 62 females, with a 
median age of 5.7 years, who had been referred for genetic testing and for whom both 
karyotype (chromosomal analysis) and the Southern Blot DNA analysis for the FMR-1 
gene mutation had been performed. The purpose of the study was to aid primary 
physicians in containing costs by simplifying criteria for FraX testing in children.  
The following six characteristics in the 9-item checklist developed by Giangreco 
and colleagues (1996) differentiated children who had FraX from children who tested 
negative for the FMR-1 gene mutation.: 1) “mental retardation,” 2) “family history of 
mental retardation and/or psychiatric disorder,” 3) “elongated face,” 4) “large or 
prominent ears,” 5) “ADHD” and 6) “autistic-like behavior” (p.612). Therefore, these six 
items were used to develop a criterion for referral for diagnostic testing for FraX. The 
items were scored similarly to the scoring of the Hagerman Fragile X Checklist, in that 
ordinal level measures, 0, 1, or 2 were employed. The mean scores on Giangreco and 
colleagues’ 6-item checklist differed significantly (p<.0001) between the FraX positive 
group (M = 8) and the control group (M = 4). Thus, Giangreco et al. (1996) concluded 
that use of the checklist as a prescreening measure, using a score of 4 or less to eliminate 
those referred for DNA testing, would have reduced the number of individuals tested by 
60%, thus increasing the cost-effectiveness of testing. Furthermore, the researchers 
reported that clinical application of the checklist, revealed 100% accuracy in 6 patients 
diagnosed to have FraX. 
Similarly, de Vries et al. (1999) developed a 7 - item checklist in which the 
following 4 items were adapted from an earlier checklist for FraX (Laing, 1991, p. 257): 
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1) “family history of mental retardation” 2) “long jaw and high wide forehead” 3) “ears-
large and protruding from the side of the head” and 4) “personality-initial shyness and 
lack of eye contact followed by friendliness and verbosity with echolalic speech.” 
Ordinal level measures (0, 1, or 2) were used for scoring in a similar manner to that of 
Hagerman et al., (1991) and Giangreco et al., (1996). However, de Vries and colleagues 
used the FMR-1 gene mutation DNA analysis as the criterion reference, whereas this 
more accurate diagnostic measure was not available for Hagerman et al.’s (1991) study.  
de Vries et al. (1999) emphasized the use of pre-selection of clinical features to 
increase the efficacy of screening programs. Additionally, one researcher, to eliminate 
challenges of inter-rater reliability conducted all physical examinations of the 896 males 
and 216 females with mental retardation of unknown origin. The data collected from 
males 16 years and younger (n=330) and the females of the same age group (n=216) were 
analyzed separately and conjointly with those of the older subjects of the same gender. 
However, there was no cross-gender comparison, which is understandable in light the 
presence of the gender specific characteristic of macroorchidism (enlarged testicles) and 
no females with FraX were identified. The data were analyzed by percentages of subjects, 
by group, exhibiting the characteristics of the checklist. In males with FraX, “family 
history of mental retardation was present for most of the sample (78%), but existed in 
only 19% of the males without FraX. Similarly, “initial shyness and lack of eye contact 
followed by friendliness and verbosity with echolalic speech” existed in 63% of the FraX 
males, but was only manifested in 4% of the non-FraX group. Each of the remaining 
items of the checklist were manifested more frequently in the males with FraX than those 
without the FraX: Macroorchidism (59%; 4%), “elongated face” (51%; 7%), “large or 
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prominent ears” (27%; 11%), “hyperextensible joints” (41%; 23%), “soft/smooth skin” 
(22%; 4%). Furthermore, de Varies and colleagues concluded the use of the checklist 
would have allowed exclusion from further testing in 86% of the sample (95% CI 0.83-
0.88) without missing any of the newly diagnosed cases. 
  
TABLE 1 
Overview and Analysis of the BIPSSI-FX with Existing Screening Checklists for FraX 
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BIPSSI-FX   
49 Items 
 5 Subscales 
 
 
 
 
 
 
 
 
 
 
Bailey et al., 
2001 
28 Items 
5  Subscales 
 
 
 
Lachiewicz  
et al.,  
(2000) 
25 Items 
4 Subscales 
  
Maes 
et al., 
(2000) 
28 Items 
2 Subscales 
 
Teisl et al.,  
(1999) 
11 Items  
Sensitized  
Affected  
State 
Consensus  
Group  
Screening  Tool 
(Reiss, et  
al., (1992) 
de Vries (1997) 
et al.,                    
8 Items 
Adapted & 
modified from 
Laing (1991) 
Giangreco 
et al., (1996) 
6 Items 
 
 
 
Reiss et al., 
(1992) 
Affected  
State Screening 
Questionnaire:  
Consensus 
Group   
17 Items 
 
Hagerman  
et al., (1991) 
Fragile X  
Checklist 
13 Items 
Developmental 
 Milestones 
Developmental 
 Milestones 
Developmental 
 Milestones 
Developmental 
 Milestones 
Developmental 
 Milestones 
Developmental 
 Milestones 
Developmental 
 Milestones 
Developmental 
 Milestones 
Developmental 
 Milestones 
1.   How old was your  
child when he/she could 
sit without support?   
 
N/A N/A N/A N/A N/A N/A N/A N/A 
 
2.   How old was your 
child when he/she began 
walking well?   
N/A N/A N/A N/A N/A N/A N/A N/A 
 
3.   At what age did your 
child first say a first 
word? 
 
“lack of sound 
imitation”(p.31) 
 
N/A N/A N/A N/A N/A N/A N/A 
4.   At what age did your 
child first wave “bye-
bye?” 
“limited or lack of 
motor imitation”   
( p.31) 
N/A N/A N/A N/A N/A N/A N/A 
5.   At what age did your 
child first respond to her 
or his name? 
“communication 
delay”( p.31) 
N/A N/A N/A N/A N/A N/A N/A 
6.   At what age was your 
child toilet trained?( urine 
and BM, with not more 
than 3 accidents while 
awake in one year) 
N/A N/A N/A N/A N/A N/A N/A N/A 
 
 
  
 
BIPSSI-FX   
 
Bailey et al.,  
(2001)   
 
 
Lachiewicz  
et al.,  
(2000)  
  
 
Maes  
et al.,  
(2000)  
 
Teisl et al.,  
(1999) 
 
  de Vries 
et al., (1997)          
Giangreco 
 et al. , 
(1996) 
 
 
Reiss et al., 
( 1992) 
  
Hagerman  
et al.,  (1991) 
 
Physical Subscale 
 
 
Physical Subscale 
 
Physical 
Subscale 
 
Physical 
Subscale 
 
Physical Subscale 
 
Physical 
Subscale 
 
Physical 
Subscale 
 
Physical 
Subscale 
 
Physical 
Subscale 
 
1.   Does your child have 
low muscle tone/ muscle 
weakness? 
“hypotonia”            
( p.31) 
N/A N/A N/A N/A N/A N/A N/A 
2.   Does your child have 
any seizures? 
N/A N/A N/A N/A N/A N/A N/A N/A 
3.   Has your child ever had 
frequent colds or nasal 
infections? 
N/A N/A N/A N/A N/A N/A N/A N/A 
4.   Has your child ever had 
cleft lip, cleft palate or an 
arched palate (top of the 
inside of the mouth)? 
“high arched 
palate”( p.31) 
“ highly 
arched 
palate" 
(p.236) 
N/A N/A N/A N/A N/A N/A 
5.   Has your child ever had 
frequent ear infections 
(more than three per year)? 
“frequent otitis 
media”( p.31) 
“more than 
five ear 
infections" 
(p.236)  
N/A N/A N/A N/A N/A N/A 
6. Does your child have 
problems with his or her 
eyes?   
“strabismus”           
( p.31) 
N/A N/A N/A N/A N/A N/A N/A 
7.   Does your child have a 
long face and/or long ears?  
a. “long or wide 
forehead”            
(p. 31)                      
b.“ long and /or 
wide and/or 
protruding ears”     
( p.31)  
 
a.“ elongated 
face" (p.236) 
b. “ears larger 
than the 75th 
percentile” 
(p.236) 
a. “narrow 
and elongated 
face”(p.211)      
b. “ large, 
protruding 
ears"  (p.211)    
N/A a. “long jaw and 
high, wide 
forehead”  
(p.661)             
b. ears ”large 
(by 
measurement) 
and protruding 
from side of 
head”  (p.661) 
a. “elongated 
face”  (p.612)        
b. " large or 
prominent 
ears”(p.612) 
N/A “large or 
prominent 
ears”(p.284) 
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BIPSSI-FX   
 
Bailey et al.,  
2001   
 
 
Lachiewicz  
et al.,  
(2000)  
  
 
Maes et al., 
 
Teisl et al.,  
(1999) 
 
  de Vries 
et al.,  (1997)         
Giangreco 
 et al. , 
(1996) 
 
 
Reiss et al., 
(1992) 
  
Hagerman  
et al.,  (1991) 
 
Social and  
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
1.   Has your child ever 
avoided looking others in 
the eye? 
a. “Avoidance of 
eye contact with 
parent”      ( p.31)       
b. “Avoidance of 
eye contact with 
examiner” ( p.31) 
“gaze 
avoidance” 
(p.236) 
“avoiding eye 
contact” 
(p.211)              
“ever had difficulty 
with avoiding  
looking others in 
the eye?”(p.283)        
“initial shyness 
and lack of eye 
contact followed 
by friendliness 
and verbosity 
with echolalic 
speech”(p.661)      
“Autistic-like 
behavior”-  
"poor eye 
contact” (p.612) 
“ever had 
difficulty with 
avoiding  
looking others in 
the eye?” ( p.63) 
“poor eye 
contact” 
(p.284) 
2.   Has your child had 
problems at home or 
school? 
N/A N/A N/A N/A N/A N/A “ever had 
problems at 
home or 
school?” ( p.63) 
N/A 
3.   Has your child had 
emotional problems? 
N/A N/A N/A “ever had any 
emotional or 
behavioral 
problems?”(p.283)     
N/A N/A “ever had any 
emotional or 
behavioral 
problems?”        
( p.63) 
N/A 
4.   Has your child had 
behavioral problems? 
N/A N/A N/A “ever have any 
emotional or 
behavioral 
problems?”(p.283)     
N/A N/A “ever have any 
emotional or 
behavioral 
problems?”        
( p.63)  
 
N/A 
5.   Has your child ever had 
treatment for emotional or 
behavioral problems? 
N/A N/A N/A  “ever received 
treatment for 
emotional or 
behavioral 
problems?"(p.283)     
N/A N/A “ever received 
treatment for 
emotional or 
behavioral 
problems?"   
(p.63)  
 
 
N/A 
6.   Has your child ever 
taken medication for 
emotional or behavioral 
problems?   
 
N/A N/A N/A “ever taken 
medication for 
emotional or 
behavioral 
problems?"(p.283)     
N/A N/A “ever taken 
medication for 
emotional or 
behavioral 
problems?"        
( p.63) 
N/A 
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BIPSSI-FX   
 
Bailey et al.,  
(2001)   
 
Lachiewicz  
et al (2000)  
 
Maes et al., 
(2000) 
 
Teisl et al.,  
(1999) 
 
  
de Vries et al.,        
  (1997) 
 
Giangreco 
et al , (1996) 
 
 
 
Reiss et al., 
(1992) 
 
Hagerman  
et al., (1991) 
 
Social and  
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
7.   Has your child ever had 
difficulty keeping his or her 
attention focused? 
 “lack of joint 
attention”   ( p.31) 
 
“short attention 
span” (p.236) 
N/A “ever had difficulty 
keeping attention 
focused?” (p.283)      
N/A “ADHD”         
(p. 612) 
“ever had difficulty 
keeping attention 
focused?”(p.63)  
“short 
attention 
span”(p.284) 
8.   Does your child talk 
with people he or she does 
not know, or has your child 
done this in the past? 
N/A N/A N/A N/A N/A N/A “ever had difficulty 
or discomfort 
socializing with 
people you don’t 
know?” ( p.63) 
N/A 
9.   Has your child ever had 
problems playing with 
people he or she does not 
know? 
N/A N/A N/A N/A N/A N/A “ever had difficulty 
with socializing 
with people you 
don't know? ” 
(p.63)  
N/A 
10.   Has your child ever 
had problems with sad or 
depressed mood? 
N/A N/A N/A “ever had difficulty 
with down or 
depressed mood?” 
(p.283)              
N/A N/A “ever had difficulty 
with down or 
depressed mood?”   
( p.63) 
N/A 
11.   Has your child ever 
had problems with 
nervousness or anxiety? 
“nervousness 
and/or anxiety”         
( p.31)         
N/A “ fearfulness” 
(p.211)              
“ever had difficulty 
with nervousness or 
anxiety?” (p.283)       
N/A N/A “ever had difficulty 
with nervousness or 
anxiety?” ( p.63) 
N/A 
12.   Has your child ever 
had a problem with hurting 
himself or herself by head 
banging or biting hands, 
arms or other parts of their 
body? 
N/A “ hand-biting" 
(p.236) 
“hand-biting” 
(p.211)              
 ever had difficulty 
with injuring 
yourself?” (p.283)      
   
N/A “autistic-like  
behavior”  
(p.612) 
“ever had difficulty 
with injuring 
yourself?”( p.63) 
“hand-biting” 
(p.284) 
 
 
 
 
 13.   Has your child ever 
picked at his or her skin or 
bit hands or fingers to the 
point of injuring self? 
 
N/A N/A “hand biting” 
(p.211)              
ever had difficulty 
with injuring 
yourself?” (p.283)      
N/A “autistic-like  
behavior” 
(p.612) 
“ever had difficulty 
with injuring 
yourself?”               
(p.63) 
hand-biting” 
(p.284) 
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BIPSSI-FX  Bailey et al.,  
(2001 )  
 
Lachiewicz  
et al.,  (2000)  
Maes et al.,  
(2000)  
Teisl et al.,  
(1999) 
 
de Vries et al., 
(1997)                  
Giangreco 
et al., (1996 )    
Reiss et al., 
(1992) 
  
Hagerman  
et al.,  (1991) 
 
Social and  
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
Social and 
Behavioral 
14.   Does your child make 
the same movements over 
and over, such as rocking, 
twirling around, or clapping 
hands or has your child 
done this in the past? 
 
N/A “hand 
flapping”(p.236)  
a.“ 
stereotypic 
hand 
movements” 
(p.211)              
b. “flapping 
hands and 
arms” (p.211)    
“ever had difficulty 
with making the 
same movements 
over and over?” 
(p.283)              
N/A “autistic-like  
behavior” 
(p.612) 
“ever had difficulty 
with making the 
same movements 
over and over?           
( p.63)”      
“hyperactivity” 
(p..284) 
15.   Has your child ever 
had problems with saying 
the same word or phrase 
over and over? 
N/A “perseverative 
speech”(p.236) 
“perseveratio
n” (p.211) 
“ever had difficulty 
with saying the 
same word or 
phrase over and 
over?” (p.283)            
“Initial shyness 
and lack eye 
contact followed 
by friendliness 
and verbosity 
with echolalic 
speech”(p.661)      
“ autistic-like 
behavior” 
(p.612) 
  
“ever had difficulty 
with saying the 
same word or 
phrase over and 
over?”    ( p.63) 
“perseverative 
speech”(p.284) 
16.   Has your child talked 
about the same subject over 
and over to the point of 
making it hard to hold a 
conversation with him or 
her? 
N/A N/A “being 
talkative” 
(p.211)              
“ever had difficulty 
talking about the 
same subject over 
and over?” (p.283)     
N/A “ autistic-like 
behavior” 
(p.612) 
“ever had difficulty 
talking about the 
same subject over 
and over?” ( p.63) 
N/A 
17.  Has your child ever had 
problems falling asleep or 
staying asleep?              
N/A N/A N/A N/A N/A N/A N/A N/A 
 
18.   Has your child ever 
had an upset or disturbed 
response to soft or light 
touch or attempted to cover 
himself or herself with 
heavy objects such as sofa 
cushions, a mattress, 
blankets, beanbag chairs, 
etc.?  
 
“tactile 
defensiveness”       
( p.31) 
“ adverse 
response to 
touch on the 
skin  
(tactile 
defensiveness) 
(p.236) “ 
 
N/A N/A N/A N/A N/A “tactilely 
defensive” 
(p.284) 
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BIPSSI-FX   Bailey et al.,  
2001   
 
Lachiewicz  
et al., (2000)  
Maes et al.,  
(2000)  
Teisl et al.,  
(1999) 
 
de Vries et  
  al., (1997)              
Giangreco 
 et al., (1996) 
 
 
 
Reiss et al., 
 (1992) 
 
Hagerman  
et al., (1991) 
 
    Biological  
    parents 
Biological 
parents 
Biological 
parents 
Biological 
parents 
Biological 
parents 
Biological 
parents 
Biological 
parents 
Biological 
parents 
Biological 
 parents 
 
 
1.   Have you or your mother, 
sisters or aunts had early 
menopause (“going through the 
change of life”) or premature 
ovarian failure? 
N/A N/A N/A N/A N/A N/A N/A N/A 
 2.   Have any women in the 
birth father’s blood family had 
early menopause (“going 
through the change of life”) or 
premature ovarian failure? 
 
N/A N/A N/A N/A N/A N/A N/A N/A 
3.   Have any women in the 
birth mother’s blood family or 
the birth father’s family, had 
cysts on the ovaries, cysts 
removed from the ovaries, or 
hysterectomy (removal of the 
uterus)? 
 
N/A N/A N/A N/A N/A N/A N/A N/A 
4.    Did the mother 
(child’s mother) ever have 
problems with feeling 
depressed or nervous before 
becoming a parent? 
N/A N/A N/A N/A N/A “Maternal 
female with 
psychiatric 
disorder”(p.612) 
N/A N/A 
5.    Did the father 
(child’s father) ever have  
problems with feeling 
depressed or nervous before 
becoming a parent? 
 
N/A N/A N/A N/A N/A N/A N/A N/A 
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BIPSSI-FX   
 
 
 
Bailey et al.,  
2001   
 
Lachiewicz  
et al., (2000)  
 
Maes et al.,  
(2000)  
Teisl et al.,  
(1999) 
 
de Vries et  
  al., (1997)            
Giangreco 
 et al., (1996) 
 
 
 
Reiss et al 
 (1992) 
 
Hagerman  
et al., (1991) 
   Biological  
    parents 
Biological 
parents 
Biological 
parents 
Biological 
parents 
Biological 
parents 
Biological 
parents 
Biological  
parents 
Biological 
parents 
Biological  
parents 
 
 
6.   Is it or has it been hard for 
anyone in birth mother’s blood 
family or birth father’s blood 
family to stop activities (such as, 
hand washing, checking locks, 
worrying, refusing to throw 
items away, computer use, 
watching television) or insist on 
doing things or having things 
done perfectly or exactly a 
certain way? 
N/A N/A N/A N/A N/A “Family history-
Maternal female 
with psychiatric 
disorder”(p.612) 
N/A N/A 
7.   Has the birth mother or the 
birth father, now (or in the past) 
drank too much alcohol, used too 
many drugs, or used drugs too 
often, either those prescribed by 
a health care worker or those not 
prescribed? 
N/A N/A N/A N/A N/A “Family history-
Maternal female 
with psychiatric 
disorder" (p.612) 
N/A N/A 
8.   Has anyone in the birth 
mother’s blood family or the birth 
father’s blood family had mental 
retardation/ developmental 
disabilities, autism, Asperger 
Syndrome or FXS? 
“ family 
history of 
mental 
retardation, 
autism, 
learning 
problems, or 
special 
education 
service”            
( p.31) 
“positive family 
history of 
developmental 
disabilities” 
(p.236)  
N/A N/A “family history 
of mental 
retardation” 
(p.661)             
“Family history- 
maternal history of 
x-linked mental 
retardation” (p.612) 
N/A “Family history 
of mental 
retardation”(p.
284) 
9.  Has the birth mother (child’s 
mother) or birth father (child’s 
father) had problems doing math?  
N/A N/A N/A N/A N/A N/A N/A N/A 
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Development of the BIPSSI-FX 
No parent response tools were found in the literature, which is surprising, given 
parents are usually the first to recognize developmental problems in their child (Bailey et 
al., 2004; Bailey et al., 2001b; Mirrett, Bailey, Roberts, & Hatton, 2004; Squires et al., 
2001). This becomes still more surprising when considering the fact that Bailey’s (2003) 
study of parents’ experience with early intervention found that parents had concerns 
about their child’s development much earlier than the diagnosis of FraX was made. 
Forness et al. (1996) found that parents are typically first to recognize their child’s social-
emotional problem. This recognition typically occurs by the age of 3 years.  
Given the lack of such a tool, early intervention has not been implemented for 
many children with the FMR-1 gene mutation during crucial early brain maturation 
(Grossman et al., 2003; Mirrett et al., 2004). The BIPSSI-FX, a parent response tool, is a 
conduit by which the “frontline” assessors, primary caregivers, may contribute to the 
earlier diagnosis. The BIPSSI-FX is the only parent response tool designed to tap the 
wealth of knowledge that parents possess about subtle characteristics of the development 
of very young children who have FraX to have been identified in recent studies. Based on 
a study of infants and toddlers with FraX in which repeated measures were obtained, 
Mirrett et al. concluded that systematic screening for developmental delays is a crucial 
aspect of decreasing the amount of time between initial parental concerns and accurate 
professional determination of the status of the child’s development.  
Squires et al. (2001) provide provocative arguments from a review of the 
literature for and against the use of parents as first-line screeners to identify 
developmental problems within the child. Furthermore, Squires et al., tested the premise 
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that parents were effective first-line screeners of their children’s social-emotional 
challenges by developing and utilizing a parent response tool, The Ages and Stages 
Questionnaire: Social-Emotional (ASQ: SE), in a geographical, economical, and racially 
diverse sample. The ASQ: SE was developed to augment the Ages and Stages 
Questionnaires (ASQ), which is a general development screening tool for children from 4 
months to 5 years of age (Squires et al. 2001) 
The ASQ is a set of 19 parent-completed questionnaires that are designed to 
identify infants and young children in various aspects of development. Although the tool 
assesses various developmental problems, specific social and emotional aspects were not 
originally included, and personnel from various early intervention programs such as Head 
Start have expressed a desire to have an instrument by which they may easily screen for 
social and emotional competence in young children. Although this need is quite great, 
few reliable and valid screening tools have been developed for the 0- to 5-year population 
that can be easily used by parents. Therefore, Squires et al. developed the ASQ: SE to 
identify infants and young children whose social and emotional development requires 
further evaluations to determine if referral for intervention services is necessary. The 
purpose of the ASQ: SE is similar to those of the aforementioned checklists for FraX. 
However, the ASQ: SE, unlike the checklists for FraX, capitalizes on the following two 
unique ingredients for early identification: 1) parents/primary caregivers as front-line 
screeners and 2) numerous assessment intervals within infancy, toddler, and preschool 
ages.  
The ASQ: SE, which spans the 3 to 63 months age period, focuses on the child’s 
social and emotional behavior in the areas of self-regulation, compliance, 
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communication, adaptive behaviors, autonomies, affect, and interaction with people. 
Items of the questionnaire target the following age intervals:  6, 12, 18, 24, 30, 36, 48, 
and 60 months, with the number of questions per age interval varying from 19, for the 
youngest group, to 33 for the oldest age group. The ASQ: SE was tested for reliability, 
validity, and utility, using a field study research design. The BIPSSI-FX, a parent 
response tool to assess for FMR-1 gene mutation “at risk” status, was developed similarly 
to the ASQ: SE because the tool is a parent response tool designed to specifically address 
the social and emotional aspects o infant and toddler development. Social and emotional 
challenges are often present in individuals with FraX who have typical cognitive 
development and who manifest none of the physiological dysmorphology of FraX 
(Hagerman, 2002). 
Not only is the BIPSSI-FX the only parent response screening instrument for 
FraX, no other checklists or psychometric screening instruments for FraX include an 
assessment for possible developmental delay. Furthermore, other checklists do not 
include an assessment of characteristics of the biological parents and extended relatives, 
despite the fact that researchers such as, Chinnery, Cartlidge, Tennant, Birchall, & 
Stenhouse (2004) have proposed the benefit of utilizing frequently manifested 
characteristics of premutation carriers to facilitate the identification of risk for FMR-1 
gene mutation in a younger generation and vice versa.  
Although various assessment tools have been utilized to describe characteristics 
of young children who have been diagnosed to have FraX, currently used psychometric 
screening tools fail to detect FMR-1 gene mutation “at risk” status both in children who 
have subtle symptoms of FraX and in children who are younger than 24-36 months of age 
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(Hagerman, 2002). The BIPSSI-FX incorporates the most frequently identified 
characteristics of FraX, along with an assessment of attributes cited as disproportionately 
higher within premutation carriers of the FMR-1 gene. The inclusion of those aspects 
facilitates the specificity of a tool to screen for FraX. Thus, it was hypothesized that 
children with FraX will score higher on the BIPSSI-FX than children with other 
developmental disabilities (Hypothesis 4 – see end of chapter 2). Furthermore, it was 
hypothesized that the BIPSSI-FX would demonstrate test-retest reliability 
(Hypothesis 2 – see end of chapter 2) and internal consistency (Hypothesis 2). 
Screening tools and psychometric measures designed to facilitate early 
identification of autism continue to proliferate (Baird et al., 2000; Baron-Cohen et al., 
1992; Baron-Cohen et al., 2000; Maestro, 2002; Robins, Fein, Barton, & Green, 2001a). 
The M-CHAT (Robins et al., 2001a), a parent response checklist, is an extension of the 
Checklist for Autism in Toddlers (CHAT, Baron-Cohen et al., 1992), which was 
established to detect autism at 18 months of age. The M-CHAT diagnoses autism early, 
but most tools developed to screen for FraX have not focused on children younger than 
24 months of age. Furthermore, to justify the need for the BIPSSI-FX, it is necessary to 
see if the BIPSSI-FX can detect FMR-1 “at risk” status more often than the M-CHAT. 
Therefore, it was hypothesized that the BIPSSI-FX would differntiate FraX from 
autistic children - no FraX more accurately than the M-CHAT. That is, it was 
anticipated that the BIPSSI-FX would predict FMR-1 gene status versus autism -no 
FraX status better than the M-CHAT (Hypothesis 6 – see end of chapter 2).  
The BIPSSI-FX is designed to identify characteristics of children who are “at risk” 
for having gene changes that are responsible for FraX. The five subscales of the    
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BIPSSI-FX and the items therein are supported by an exhaustive review of the literature 
summarized in the paragraphs that follow. 
Developmental Subscale 
Significant developmental delays are often evident in the early years of children 
who have FraX (Bailey, Hatton, Skinner, & Mesibov, 2001b; Hagerman et al., 2002; 
Heverly, 2000-2001; Lachiewicz et al., Keysor, Mazzocco, McLeod, & Hoehn-Saric, 
2002, p. 179) in a review of the literature regarding females with FraX - full mutation, 
emphasize the “logic” of a “developmental approach” to frame the various aspects of 
FraX, such as cognitive, social, emotional, and behavioral functioning. Furthermore, 
Keysor et al., (2002) note that “only recently have efforts begun to identify the 
developmental trajectory of FraX in infants and toddlers (p. 179).” Consequently, limited 
data are available regarding the achievement of early developmental milestones in 
individuals with FraX.  
Bailey et al. (2001a), in a study to distinguish differences between children with 
FraX and those who have autism - no FraX found developmental delay to be one of the 
earliest indicators of both FraX and autism. Bailey and colleagues used various 
diagnostic and screening inventories such as the Battelle Developmental Inventory (BDI) 
to help to differentiate characteristics of FraX and autism. The BDI, which spans the age 
range from birth to 96 months of age and measures development in five areas, namely, 
personal-social, adaptive, cognitive, motor, and communication, was used to compare the 
overall delay and to determine a pattern of delay in both children with FraX and those 
with autism. The study showed that having both the FraX and autism might cause a more 
significant developmental delay than FraX without the diagnosis of autism. The Bailey et 
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al. (2001b) study heavily supports the inclusion of the Developmental Subscale within the 
BIPSSI-FX.  
Physical Subscale 
The literature identifies physical manifestations, which are likely to be seen in 
children with FraX. The common findings assessed in the BIPSSI-FX include seizure 
activity, frequent ear infections, frequent colds and nasal infections, low muscle tone or 
muscle weakness, and strabismus or vision problems in general. Seizure activity is 
evident in about 20% of the children with FraX (Hagerman, 1997; Incorpora, Sorge, 
Sorge & Pavone, 2002). The American Academy of Pediatrics recommends guidelines to 
assist pediatricians caring for children with FraX (Desposito et al., 1996). Those 
guidelines include obtaining an electroencephalogram and assessing the seizure history of 
children ages one through 5 years (Desposito et al., 1996).  
Another health concern commonly encountered in children with FraX is frequent 
middle ear infection (Desposito et al., 1996; Hagerman, 1987; Hagerman, 1997; Turk& 
Patton, 2000; Zissel & Roberts, 2003). Frequent ear infections which occur in 
approximately 60% of children with the disorder (Turk & Patton, 2000), directly affect 
speech and language development. Oftentimes children with FraX also suffer from 
frequent sinus infections as well (Hagerman, 2002). Low muscle tone or connective 
tissue defects or disorders are responsible for many of the physical characteristics of 
children with FraX (Lachiewicz et al., 2000). A study by Hjalgrim, Hansen, Brondum-
Nielsen, Nolting, & Kjaer (2000) suggested that there is a malfunction in the supporting 
tissue during fetal development. Finally, strabismus and visual problems in general are 
seen frequently in children with FraX (Desposito et al., 1996; Hagerman, 1997; Hatton, 
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Buckley, Lachiewicz, & Roberts, 1998; Lachiewicz et al., 2000; Turk & Patton, 2000). 
Of even greater cause for alarm is Desposito et al.’s (1996) recommendation of vision 
exams as early as 6 to 12 months of age for children who have FraX, based upon their 
finding that strabismus occurs in nearly 40% of children who have FraX.  
FraX occurs relatively equally in all racial and ethnic groups (Crawford et al., 
1999). It is a condition of major epidemiological importance among mentally 
handicapped males and “must be considered in the differential diagnoses of a child with 
developmental delay, mental retardation, or learning disability” (Pimentel, 1999, 639). 
Cognitive Subscale 
Approximately 85% of boys with FraX have mental retardation (Hagerman, 
1997). Among children with FraX, boys are more likely to have mental retardation 
whereas girls are more likely to have a learning disability with normal intelligence 
(Hagerman et al., 1996). According to Dyer-Friedman, et al. (2002), girls with FraX had 
somewhat higher cognitive abilities than did boys with FraX. Females with FraX tend to 
struggle with math, but may perform exceptionally well in reading and spelling; in 
contrast, reading often poses problems for boys (Hagerman, 1997; Mazzocco, & Myers, 
2003). Additionally, speech and language present special difficulties, more often 
affecting boys than girls. Around 10% of children with FraX have severe delays in 
language development and remain nonverbal for the first 6-8 years of life, and possibly 
even longer (Hagerman, 1997). When speech develops, rapid speech associated with 
mumbling and echolalia is common in children with FraX especially in boys. 
Perseveration is exhibited when a question is asked repeatedly, even after an answer has 
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been given (Hagerman, 1997). Inappropriate outbursts and tantrums are also common in 
FraX, but are manifested more often in boys.  
Speech and language delays lead to underdeveloped or slow learning. A common 
means for determining intellectual and cognitive functioning is IQ testing. The average 
score for any person on a standardized IQ test is 100. According to Hagerman (2002), 
approximately 50-70% of girls with the full mutation have an intellectual deficit with an 
IQ under 85, and when mental retardation occurs, it is usually mild (IQ 50-70), whereas 
the IQ of boys with a FraX-full mutation is in the 40s. The majority of children with FraX 
score below average on IQ tests. Limited FMR-1 protein production caused by a person 
having some cells with the premutation and other cells with the full mutation can cause 
higher intellectual functioning (Hagerman, 1997). These children may still face learning 
obstacles, but can excel in some areas of cognitive functioning particularly with 
individualized special education services. Due to the delayed and underdeveloped 
cognitive functioning of children with FraX, they are typically eligible for special 
education services, and cognitive outcomes become enhanced with individualized special 
education (Bailey et al., 2001; Braden, 2002; Hagerman, 1997; Hodapp, 1999). 
Social/Behavioral Subscale 
The Social /Behavioral Subscale is an adaptation of the 11 emotional/behavioral 
items of the Consensus Group Screening Checklist for FraX (Reiss et al., 1992). 
Behavioral symptoms associated with FraX tend to be both the most endearing traits as 
well as the most challenging ones. For example, deVries et al (1997) included a 
personality trait characterized by shyness and poor eye contact, including friendliness, 
excessive conversation, and perseverative speech. This duality, poses difficulties for 
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those involved in the care and education of those affected with FraX. While males tend to 
be very socially engaging, they may alternately and sometimes simultaneously exhibit 
signs of social anxiety. They tend to avoid eye contact during conversations and to speak 
in imitative, rapid, or perseverative ways. Other autistic-like behaviors are also frequently 
exhibited, such as withdrawal from others and self-stimulatory behaviors. Individuals 
with FraX frequently have problems with hyperactivity, short attention spans, difficulty 
with concentrating, and aggressive behaviors (Baumgardner, Reiss, Freund, & Abrams, 
1995; Hagerman, 2002). Reports of the incidence of FraX among those diagnosed with 
autism vary (Blomquist, Bohman, Edvinsson, & Gillberg, 1985; Fisch, Cohen, Jenkins, & 
Brown, 1988). However, it is widely accepted that using DSM-IV-TR criteria, 16 to 17 % 
of those identified as autistic also have FraX (Hagerman, 2002). The majority of males 
who have the FraX - full-mutation exhibit autistic-like behaviors (Hagerman, 2002).  
Furthermore, a study (Teisl et al., 1999) of 55 preschool and school-aged children 
with FraX, full mutation found that children with the full-mutation were more likely than 
the controls to be described as nervous or anxious, and to regularly engage in 
perseverative speech and /or other challenging behaviors. The intense reactions to 
auditory, tactile, visual, and olfactory stimuli in persons with the FraX mutation have 
been associated with anxiety, aggression, hyperactivity, and hyperactive arousal 
(Hagerman, 2002). Miller et al.’s (1999) study of 25 individuals with FraX (16 full-
mutations) found that individuals with FraX have a physiologically based enhancement 
of reactions to sensory stimuli. 
Roberts, Hennon, and Anderson’s (2003) review of the literature reveals support 
for Items 1, 2, 3, and 4 of the Social Behavioral Subscale of the BIPSSI-FX which relate 
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to avoiding looking others in the eye, problems at school or home, emotional problems, 
and behavioral problems. Furthermore, Roberts and colleagues’ (2003) study of 43 males 
with FraX, full-mutation between the ages of 2 to 7 years, showed that eight of the 
children exhibited characteristics of autism. Additionally, they found that the children 
had delayed language development with the expressive language skills developing more 
slowly than the receptive language skills over time. The boys with FraX showed 
considerable delay in receptive language development in that they developed receptive 
language at about one-half the rate expected for typically developing children and they 
developed expressive language at about one-third the rate. Roberts et al., (2003) linked 
cognitive and developmental characteristics to the receptive and expressive language 
development delay.  
Richdale (2003) found that children with FraX express significantly greater 
difficulty fall asleep. Furthermore, Hessl et al.(2001) in their study of 120 children (80 
boys and 40 girls) with the FraX - full mutation and their unaffected siblings, between the 
ages of 6 to 17 years, reported group differences that lend credence to the inclusion of the 
following items in the Social Behavioral Subscale:   2) “problems at home or school,” 3) 
“emotional problems,” 4) “behavioral problems,” 5) “treatment for emotional or 
behavioral problems,” 7) “difficulty keeping focus,” 10) “sad or depressed mood,”       
11) “nervousness or anxiety,” 17) “problems falling asleep or staying asleep. The 
variables measured in the study were behavioral problems, somatic complaints, 
delinquent behavior, aggressive behavior, anxiety/depression, social problems, attention 
problems, thought problems, and environmental problems. The children with FraX had 
significantly higher scores on the CBCL than their non-affected siblings. Thus, in the 
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current study it was hypothesized that the BIPSSI-FX would demonstrate concurrent 
validity with the CBCL and the Consensus Group Questionnaire for Fragile X 
(Hypothesis 1 – see end of chapter 2). Furthermore, it was hypothesized that children 
with FraX would score higher on the BIPSSI-FX than children who do not have the 
FMR-1 gene mutation (Hypothesis 3). 
In addition to an assessment of developmental milestones, physical development, 
cognitive development, and social/emotional behaviors commonly exhibited by children 
with FraX, the BIPSSI-FX uniquely includes an assessment of characteristics that have 
been associated with carriers of FraX in either the premutation or the full-mutation state. 
Biological Parent Subscale 
 FMR-1 gene alterations are transmitted in an X-linked manner and thus may be 
passed to offspring by the mother or father. Therefore, the inclusion of key characteristics 
of males and females with FraX is logical to facilitate early identification of infants and 
toddlers “at risk” for FraX.  
A mother has a 50% chance of transmitting FraX to a male or female child 
because a female typically has two X chromosomes on the 23rd pair, which is responsible 
for determining gender. The mother contributes an X chromosome to each child she 
conceives. On the other hand, a male’s 23rd chromosome pair consists of an X and a Y 
chromosome. Therefore, a man contributes an X chromosome to combine with the 
woman’s X chromosome to reproduce a female. Thus a father who has FraX, 
premutation, has a 100% chance of transmitting the FraX - premutation to each of his 
daughters. On the contrary, since a father contributes a Y chromosome to a male child, he 
has a 0% chance of transmitting FraX to a son. 
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Not only does the prevalence of FraX necessitate focus on diagnosing and 
therapeutic interventions, but also the emerging data regarding the atypical transmission 
and phenotypic expression warrants close focus on this syndrome (Shapiro, 1997; 
Sherman, Jacobs, & Morton, 1985). The genetic expression of FraX is atypical in that 
some female carriers may have clinical symptoms of the disorder and some males who 
inherited the gene may not be affected clinically (Braat, Smits, & Thomas, 1999; Franke 
et al., 1996; Hagerman et al., 1992; Sherman et al., 1985). This phenomenon is of 
significance, especially in light of the increased number of individuals who may possibly 
experience behavioral or physiological maladies because of being a premutation-state 
carrier of the FMR-1 gene (Dorn, Mazzocco & Hagerman, 1994; Franke et al., 1996).  
Premature Ovarian Failure, Ovarian Cysts, and Hysterectomy. Premature ovarian 
failure (POF), a cessation of ovarian function at the age of less than 40 years after normal 
development, is characterized by the occurrence of amenorrhea (absence of menstruation) 
with low estrogen levels (Laml, Preyer, Umek, Hengstschlager, & Hanzal, 2002). 
Allingham-Hawkins et al. (1999) conducted an international collaborative study 
examining premature menopause in FraX carriers in which 760 women with a family 
history of FraX were surveyed about their FraX status and menstrual and reproductive 
histories. Hawkins and colleagues found a significant association between FraX 
premutation status and premature menopause. Similarly, Giovannucci - Uzielli et al., 
(1999) in their study of 108 women with POF, found 6.5% of the subjects had FraX 
premutation. However, contrary to these findings, Kenneson, Cramer & Warren (1997) 
screened 216 women who had experienced early menopause at <40 years, but no FraX 
premutation alleles were found. Based on these findings, Kenneson et al. (1997) 
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concluded that FraX premutation is not a major risk factor for early menopause. It is 
plausible that Kenneson and colleagues’ divergent findings are due to a lack of control 
for other causes of POF. As menopause may vary from person to person with a slight 
difference of a couple of years from the normal age, studies show that females with FraX, 
premutation experience menopause much earlier than the general population of women. 
Giovannucci-Uzielli et al. found that 13 to 25% of FraX carriers experienced premature 
ovarian failure before the age of 40 years. 
A preponderance of empirical data addressing a greater incidence of irregularities 
of hormone functions manifested by POF, ovarian cysts, and hysterectomy in women, 
who are premutation carriers of the FMR-1 gene, supports the appropriateness of the 
inclusions of the assessment of these attributes in biological female relatives of a child for 
whom a psychometric screening inventory is completed. Therefore screening for FraX - 
premutation of women with premature ovarian failure, cysts on the ovaries, and 
hysterectomy, will be helpful in effective screening of young children who may be “at 
risk” for FraX.  
 Depression, Anxiety, and Attention Difficulties. A study of female carriers of the 
FMR-1 gene found a statistically significant behavioral phenotype (depression and 
anxiety) in intellectually normal and above normal females (Franke et al., 1996). 
Additionally, a study of male premutation carriers showed a higher incidence of 
behaviors related to adult Attention Deficit Hyperactivity Disorder, alcohol abuse, and 
dependence and obsessive-compulsive disorders (Dorn et al., 1994). Similarly, Tamm, 
Menon, Johnston, Hessl, & Reiss (2002), reported that females with FraX demonstrate 
impulsivity or problems with inhibition of behavior, which manifest as difficulties 
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focusing and organizing tasks. Einfeld, Tonge, and Turner’s (1999) longitudinal study (7 
years) of behavioral and emotional problems in young people with FraX found 
substantial persistence of an overall level of behavioral and emotional problems. 
Furthermore, Einfeld and colleagues (1999) found children with FraX could be 
distinguished from other children with intellectual disability by greater levels of shyness, 
gaze avoidance, and speech peculiarities on Developmental Behavior Checklist (DBC). 
However, the FraX group scored significantly lower on the “antisocial” subscale of the 
DBC (Einfeld et al., 1999), indicating a desire to interact with others despite having 
concurrent behaviors which inhibit social interaction.  
Difficulties with Math. Math skills go hand in hand with reading, spelling, and 
writing; therefore, a math disability can be correlated with lack of reading and writing 
skills but may also hinder academic performance in and of themselves. Mazzocco (2001) 
defined math difficulty as a weakness in arithmetic performance relative to performance 
in other academic or cognitive domains, with particular attention given to participants 
whose scores fell within the range of the bottom 10th percentile of a normative sample. 
Significant deficits in arithmetic skills were demonstrated in females with FraX - full 
mutation. Similarly, Tamm et al. (2002) in a study of cognitive processing in females 
with FraX - full mutation found short-term memory deficits, higher verbal than 
performance IQ scores, and poor arithmetic performance on neuropsychological tests. 
Thus, the inclusion of an assessment of math abilities in the Biological Parent Subscale is 
supported by scientific evidence.  
The aforementioned characteristics in biological parents, siblings, and extended 
relatives are frequently expressed and may be diagnosed, while the relative 
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simultaneously deals with stressful multi-systemic challenges of caring for the child with 
FraX. Often, the primary caregiver of a child who has FraX, concurrently has the dual 
challenge of coping with the challenges of the child as well as his or her own physical 
anomalies such as:  a) POF, which often results in bone density loss and emotional 
challenges due to hormonal imbalances(Allingham-Hawkins et al.,1999; Giovannucci-
Uzielli et al.,1999; Laml et al., 2002; Murray et al., 2000; Sherman, 2000); b)connective 
tissue weaknesses and visual problems (Amin & Maino,1995; Hagerman, 2002; Steyaert, 
Legius, Borghgraef, & Fryns, 2002); and c) possibly degenerative neurological changes 
such as those manifested in Fragile X Associated Tremors and Ataxia Syndrome (FXTAS 
- Hagerman et al., 2004). Therefore, it was hypothesized that scores on the Biological 
Parent Subscale would differ between parents of children with FraX and parents of 
children without the FMR-1 gene mutation, including children who have 
developmental delays of other origins (Hypothesis 5).  
Comparison of Autism and Fragile X Syndrome 
An association between autism and FraX has been described, although a diagnosis 
of FraX does not implicate autism, or vice versa (Mazzocco, 2000). Autism and FraX are 
two distinctly different disorders. Autism is a developmental disorder characterized by 
social and communicative abnormalities typically displayed within the first three years of 
life and is diagnosed by clinical interviews, direct assessment and behavioral ratings 
(Bailey, Hatton, Mesibov, Ament, & Skinner, 2000). Autism is believed to have multiple 
causes, including genetics; however, most persons with autism have some form of mental 
retardation. Because the majority of males with FraX - full mutation exhibit autistic 
features and approximately 15 % meet the Diagnostic and Statistical Manual-Text 
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Revision (DSM IV-TR) criteria for autism, symptomatic behaviors of autism were 
included in the BIPSSI-FX to differentiate children with FraX and autism from those only 
with autism. 
FraX is present at birth and is diagnosed definitively with 99% accuracy by 
genetic testing (Crawford et al., 2001). Like autism, FraX is characterized by 
communication delays and mental retardation. There has been a considerable amount of 
research comparing FraX and autism as two distinct disorders, but a differentiation of the 
autistic-like behaviors of FraX and the DSM-IV TR diagnosis of autism is emerging. 
Bailey et al. (2001a) applied various diagnostic and screening inventories to help 
differentiate characteristics of FraX and autism. The Battelle Developmental Inventory 
(BDI), which spans the age range from birth to 96 months of age and measures the 
cognitive development in five areas namely:  personal-social, adaptive, cognitive, motor, 
and communication, was used to compare the overall delay and to determine a pattern of 
delay in both children with FraX and those with autism. Additionally, the ABILITIES 
Index was used to assess functional impairment of the two groups; and temperament was 
assessed using the Behavioral-Style Questionnaire (BSQ), which is a 100-item parent 
report scale in which scores in nine different areas of temperament are obtained. The 
Bailey et al. study showed that having both FraX and autism might cause a more 
significant developmental delay than FraX without the diagnosis of autism. The overall 
difference in the development of children with FraX without autism compared with the 
development of children who have autism - no FraX, was not significant. However, 
children with FraX and autism had greater impairment in behavior, social skills, and 
temperament than the children with FraX without autism. These findings suggest the 
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behavior of children with FraX and autistic are affected more severely than children with 
FraX alone or autism alone. Therefore, children with FraX will differ from those with 
Autism, PDD-NOS, and Asperger Syndrome more on the BIPSSI-FX than on the 
M-CHAT (Hypothesis 6 – Study II). 
Summary of Hypotheses 
In summary, the following hypotheses emanate from the review of the literature 
and were tested:  
Hypothesis 1 - The BIPSSI-FX will measure FMR-1 gene mutation "at risk” status 
in young children validly, as indicated by concurrent validity with the CBCL and the 
Consensus Questionnaire for Fragile X (Study I). 
Hypothesis 2 - The BIPSSI-FX will measure FMR-1 gene mutation "at risk” status 
in young children reliably as indicated by test-retest reliability (Study 1) and internal 
consistency (Study I, Study II); 
Hypothesis 3 - Children with FMR-1 gene mutation will score significantly higher 
on the BIPSSI-FX than children without the gene mutation (Study II). 
Hypothesis 4 - Children with FMR-1 full mutation will score higher on the 
BIPSSI-FX than children who have other types of developmental disabilities (Study II). 
Hypothesis 5 – Parents of children with the FMR-1 gene mutation will score 
higher on the BIPSSI-FX Biological Parent Subscale than parents of children without the 
gene mutation (Study II).  
Hypothesis 6 - Children with FraX will differ from those with autism, PDD-NOS, 
and Asperger syndrome more on the BIPSSI - FX than on the M-CHAT (Study II). 
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CHAPTER THREE 
METHOD 
Research Approach and Design 
This research study featured a comparative exploratory field study design (Polit & 
Hungler, 1991). The comparative exploratory design was appropriate for use in the study 
because of the continued need for a cost-effective screening tool by which young children 
positive for the FMR-1 gene mutation may be identified(Teisl et al., 1999). The BIPSSI-
FX was designed to address the special challenges of assessing very young children by 
way of a screening instrument that may be appropriately used in both clinical and in non-
clinical settings. The tool was designed to screen for FMR-1 gene alteration “risk” in 
children 12 months through 84 months of age.  
The reliability and validity of the original BIPSSI-FX was evaluated with a small 
sample of extended family members of individuals diagnosed with FraX. The results of 
this first study were used to revise the BIPPSI-FX. The revised BIPSSI-FX was further 
tested with a sample of parents of culturally, geographically, ethnically, and 
socioeconomically diverse children. 
Study Samples 
Study I. A pilot study of 27 children between the ages of 12 months to 18 years of 
age and their primary caregiver in a large extended family in which there is a relative 
diagnosed with FraX was conducted. The sample consisted of 15 males and 12 females, 
having a mean age of 9.67 years. Twenty-one children in the sample were between the 
ages of 6-18 years and the remaining six were between 12 months to 84 months of age. 
All of the children were African-American and most resided in the delta region of a 
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southern portion of the United States. The primary care givers of the children consisted of 
13 mothers, 2 fathers, and 1 grandmother, between 31 years to 42 years of age, with a 
mean age of 39 years. Six parents did not provide information regarding their age. The 
educational attainment ranged from some college to doctorate. Seventy-nine percent 
(n=11)of the parents held a bachelor's degree or higher. However, two parents did not list 
a level of educational attainment. Specific data regarding income were not gathered due 
to participants' concerns for anonymity and privacy. 
Study II. The small sample size of the pilot study along with the absence of 
geographical and ethnic diversity necessitated further testing of the BIPSSI-FX. Thus, a 
convenience sample of 359 primary caregivers of children ages 12 months to 84 months 
of age participated in study II. The primary caregivers' children had been previously 
diagnosed, using blood DNA analysis, to have FraX in the full mutation state (>200 CGG 
repeats) or the FMR-1 gene in the premutation state (50-200 CGG repeats). Also included 
for comparison were groups of primary caregivers of children who had been diagnosed to 
have autism, Pervasive Developmental Disorder – Not Otherwise Specified (PDD-NOS) 
or Asperger Syndrome, but had not received a diagnosis of FraX. Furthermore, a group of 
parents of typically developing children who had no diagnoses of learning disorders 
and/or behavioral disorders and did not have other biological children diagnosed with 
FraX.  
A majority of the participants was Caucasian (84.68 %), but more than five racial 
or ethnic groups constituted the sample. The caregiver's relationship to the focal child 
was primarily “mother” (85%); 3.1 percent of the respondents were fathers. Most of the 
primary caregivers were married, remarried or partnered (n = 325, 90.53%). Less than ten 
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percent described themselves as single, divorce, separated or widowed. Educational 
attainment was generally high, with 208 (57.94%) having attained bachelors, masters, or 
doctoral degrees. Two-hundred-seventy (75.21%) primary caregivers had an annual 
household income of greater than $35,000. The median income of the respondents was 
$50,001 to $75,000 per year. The average age of the parent was 35.13 years and the 
children ranged in age from 11 months 20 days to 7 years and 4 days with the average 
age being 4.07 years. Most of the parents endorsed their religious preference as Christian 
(Protestant 52%, Catholic 25%). The sample consisted of participants from thirty-eight 
states, with no state representing more than 8.08% of the sample and most were from the 
United States (n =  87.47%). However, 14 countries from four continents (Europe, 
Australia, Asia, and Africa) were represented, in addition to North America. Table 2 
provides a summary of key demographic data. 
 
 
 
 
 
 
 
 
 
  53 
 
 
Table 2  
Demographic Information: Study II 
A. Gender, Age, and Relationship 
 
Variable                                         Mean            (+ SD)   Frequency    % 
       
Child age    4.07 years     (1.55) 
Child gender     
 Male        166  46.24  
 Female        48  13.37 
 No gender noted by caregiver     145  40.39 
 Primary caregiver’s gender     
 Male          16    4.46 
 Female       343  95.54 
 
Caregiver relationship 
 Mother       304  84.68 
 Father          11    3.06 
 Grandmother           3    .84 
 Adoptive mom         12    3.34 
 Foster parent                                          2    0.56 
 Relationship not provided        29                    8.08  
Primary Caregivers’ Age 
     35.13  (6.54)   
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B. Family Income Level Per Year  
  
 Frequency %
Other 12 3.34
Less than 10,000 1 .28
 
10,001 - 20,000 
28 7.79
 
20,001 - 25,000 
17 4.73
 
25,001 - 35,000 
31 8.64
 
35,001 - 50,000 
62 17.27
 
50,001 - 75,000 
86 23.96
 
75,001 - 100,000 
56 15.6
 
100,001 and Up 66 18.38
Total                               359 100.0
 (1.90)  
 
C. Primary Caregivers’ Educational Attainment                      
Attainment                                        Frequency                    % 
Other             3    0.83 
Grammar school         2    0.55 
High school                   41  11.36 
Some college                  107  29.64 
College degree                 133  36.84 
Masters degree                    64  17.73 
Doctorate                    11   3.05 
 
 
  55 
 
 
D. Primary Caregivers’ Marital Status 
Married        308  85.79 
Single           12    3.34 
Divorced          12    3.34 
Separated          7    1.95 
Remarried            2    .56 
Partnered          15    4.18 
Widowed            3    .84 
E. Primary Caregivers’ Ethnic Background 
Caucasian        304  84.68 
African-American           7    1.95 
Hispanic          17    4.74 
Native American           4    1.11 
Asian/Pacific Islander         17    4.74 
Biracial            1    .28 
Other             9  2.51 
Total         359         100.00 
 
 
Procedure 
Study I 
The researcher completed a small pilot study of 27 children between the ages of 
12 months to 18 years of age and their primary caregiver in a large extended family in 
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which there was a relative diagnosed with FraX, before the larger internet-facilitated 
study. Prior to the initiation of the study, the researcher obtained the approval of the 
Oklahoma State University Institutional Review Board to conduct the research (see 
Appendix C). Additionally, each primary caregiver signed an Informed Consent Form 
and each child who was able to write gave informed Assent (See Appendix D). The 
primary caregiver of each child completed the BIPSSI-FX twice, one month apart, to 
assess test-retest reliability. Additionally, to facilitate the assessment of concurrent 
validity the primary caregivers completed the following: 1) The Child Behavior Checklist 
(CBCL) and 2) the Consensus Group Screening Questionnaire for Fragile X (CGSQ-FX). 
Furthermore, the primary caregivers collected a buccal (cheek) cell swab sample from 
their child, which is comparable to brushing the child's teeth. The extracted DNA was 
analyzed for FMR-1 gene to determine carrier status. The swab was placed in the 
container provided by the researcher, labeled with the last four digits of the child's social 
security number, and mailed by the parent in the prepaid and addressed priority mail 
envelope to the research assistant. The research assistant immediately (within 24 hours) 
took the samples to a local medical genetics laboratory for safe storage in a temperature 
controlled (non-cycling) freezer to preserve the integrity of the DNA and thus facilitate 
accurate analysis. The samples were kept in the freezer until most of the specimens were 
received. Additionally the assistant organized the completed research paper and pencil 
measures, charted the forms as received and the date. The assistant also verified that the 
forms were void of identifying information such as primary caregiver and child's name. 
Additionally the assistant insured that each form was coded appropriately. The researcher 
retrieved the coded swabs from the laboratory; separated the swabs into two packages, 
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each consisting of one of each child's swabs; and wrapped the swabs in bubble wrap and 
mailed packages via Express mail to the research laboratory responsible for DNA 
analysis. 
The DNA analyses were completed in a research laboratory in which this method 
of screening for FMR-1 gene changes is conducted on an ongoing basis. Results from the 
biological analyses were correlated with the results of the psychometric measures. 
However, the lack of amplification of DNA in several of the specimens, despite repeated 
collection of the buccal cell swabs along with serendipitous findings rendered the results 
inconclusive. The buccal swab method of collecting DNA for analysis of the FMR -1 
gene is a relatively new process and is conducted in only a few research laboratories in 
the United States. However, the reliability and validity of the analysis of DNA for the 
FMR-1 gene mutation from buccal cell swab samples is reported in the literature 
(Hagerman, Wilson, Staley, Lang, Fan, Ulhorn et al., 1994). Nonetheless, this DNA 
collection method is not used in any clinical laboratories for the purpose of FMR-1 gene 
mutation analysis. It is highly plausible, that the validity of the FMR-1 gene mutation 
analyses is questionable because of the great difficulty in collecting sufficient amounts of 
DNA by the buccal cell swab method. 
Study II 
Prior to the initiation of the study, application to conduct the research was made 
with the institutional review board of Oklahoma State University. After permission to 
conduct the research was obtained (Appendix E), primary caregivers of children from one 
of seven groups were recruited to participate in the study. Each parent or primary 
caregiver completed and submitted, via Internet, the revised BIPSSI-FX, the M-CHAT, a 
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Primary Caregiver Information Profile, a Diagnosis Information form and acknowledged 
a statement of informed consent contained in the How to Participate information sheet 
(see Appendix F). Instructions for completion of the study were clearly delineated on the 
recruitment website, http://langston.osu-tulsa.okstate.edu/vthomas (see Appendix K). 
Recruitment of Subjects  
The samples of parents were recruited from child-oriented Internet listserv groups 
and organizations. Additionally, after obtaining permission from various listserv masters, 
the principal investigator posted a notice recruiting parents of children diagnosed to have 
a developmental disability or of typically developing children (see Appendix J). A 
website (http://langston.osu-tulsa.okstate.edu/vthomas) specifically designed for the 
study provided a mechanism by which the primary caregivers completed the 
questionnaires online and returned the surveys by way of encrypted automated return 
submission, in an Access database, to the computer server of the university, which 
developed and sponsored the website. The researcher received approval from the 
Oklahoma State University Institutional Review Board to alter the inclusion criteria for 
the study to allow children in the comparison diagnosis groups for whom FraX had not 
been ruled out by DNA testing. The website and the recruitment letter reflected this 
change. The recruitment website remained active for 3 months for data collection and the 
website remained active for an additional 9 months following data collection, for 
purposes of disseminating aggregate data from the study, thanking parents for 
participating, and providing links to related websites likely to provide helpful information 
to parents. Confidentiality was maintained and anonymity was protected in all situations. 
Results of the aggregate data analyses and interpretations were provided at the conclusion 
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of the study by a statement posted to each of the aforementioned Listserv groups and by 
way of a link to the research study website. 
Rationale for Internet Data Collection Method 
The Internet has become an important communication tool in modern society 
(Frankel & Sanyin, 1999). Potentially, the Internet may change the way we conduct 
scholarly research (Harris & Dersch, 1999). The Internet can be very beneficial in the 
areas of participant recruitment and data collection. Internet sites that house 
questionnaires or other forms of survey instruments are not significantly different from 
other research involving questionnaires. Researchers to ensure results that are both 
reliable and valid must adhere to specific guidelines and protocols. Despite the 
similarities between traditional (pen and paper) and Internet conducted research, there are 
differences that must be addressed (Harris & Dersch; see Appendix L for more 
information). In order to address these problems the principal investigator invited 
participants to add comments or clarify their responses at the end of all questionnaires.       
Inclusion Criteria for Study II 
Diagnosis Groups 
Fragile X - Full Mutation Group. This group included males and females aged 12 
months through 84 months of age. By parent report, the children must have results of 
DNA testing that indicate more than 200 CGG repeats on the FMR-1 gene in cells 
analyzed and have been diagnosed by a qualified health-care professional or geneticist to 
have FraX. The primary caregiver of the child had to be able to read and typewrite in 
English or Spanish. 
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Autism with no FraX, nor Asperger. This group included males and females aged 
12 months through 84 months of age. By primary caregiver report, a qualified health-care 
professional has made the diagnosis of autism, but there is no diagnosis of FraX nor 
Asperger Syndrome. The primary caregiver of the child had to be able to read and 
typewrite in English or Spanish. 
Pervasive Developmental Disability Not Otherwise Specified (PDD-NOS). This 
group included males and females aged 12 months through 84 months of age. By primary 
caregiver report, a qualified health-care professional had made the diagnosis of PDD-
NOS, but there is no diagnosis of FraX nor Asperger Syndrome. The primary caregiver of 
the child had to be able to read and typewrite in English or Spanish. 
Asperger with no FraX. This group included males and females aged 12 months 
through 84 months of age. By primary caregiver report, a qualified health-care 
professional has made the diagnosis of Asperger Syndrome, but there is no diagnosis of 
FraX. The primary caregiver of the child had to be able to read and typewrite in English 
or Spanish. 
Down Syndrome Group. This group included males and females aged 12 months 
through 84 months. By primary caregiver report, children have been diagnosed by a 
qualified health-care professional to have Down Syndrome (Trisomy 21). Children had 
not received a diagnosis of autism, nor a diagnosis of FraX or Asperger Syndrome. The 
primary caregiver of the child had to be able to read and typewrite in English or Spanish. 
Typically Developing Group (No diagnosis). This group included males and 
females aged12 months through 84 months of age. By primary caregiver report, the child 
exhibits typical growth and development, is free of chronic or terminal illnesses, and has 
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no known physical, cognitive, or behavioral impairments. The primary caregiver of the 
child had to be able to read and typewrite in English or Spanish. 
Measures 
Study I 
Each parent or legal guardian (the primary caregiver) completed the BIPSSI-FX, 
the Consensus Group State Screening Questionnaire for Fragile X, the Child Behavioral 
Checklist(CBCL), a family background information background form and a loosely 
structure questionnaire, while keeping in mind his or her child who was participating in 
the research study. Furthermore, each parent collected a sample of his or her child's 
DNA. 
Biopsychosocial Screening Inventory for Fragile X 
The researcher designed the BIPSSI-FX to be completed by a child’s primary 
caregiver (see Appendix A). This 35-item Likert scale-type instrument, consists of the 
following five subscales: Developmental Milestones, Physical, Social and Behavioral, 
Cognitive, and Biological Parent. The Social/Behavioral Subscale was adapted from the 
social/emotional items of the Consensus Group Screening Questionnaire for Fragile X –
CGSQ-FX (Reiss et al, 1992). 
Consensus Group Screening Questionnaire for Fragile X 
The CGSQ-FX (Reiss et al., 1992) is a 19 item, 3-point scale (“yes” “no” “no 
information”) screening questionnaire designed for use by clinicians interviewing 
patients themselves or parents, guardians or other caregivers (see Appendix B). A group 
of experts in diagnosing and treating individuals with FraX developed this tool. 
Reliability and validity data have not been reported for the complete CGSQ-FX. 
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However, Teisl et al., 1999 presented reliability and validity data for the 11 items of the 
more sensitive abridged version of this instrument. Teisl and colleagues reported a 100% 
level of sensitivity and specificity of the sensitized screening tool for FraX, among 
preschoolers, in a matched sample of 110 children. A detailed report of the study was 
presented in Chapter 2.  
Child Behavior Checklist 
The CBCL - Ages 1-1/2 years to 5 years (Achenbach, 2001) was completed for 
children aged 25-71 months, whereas the CBCL - Ages 6-18 (Achenbach, 2001) was 
completed for children older than 71 months. The CBCL was designed to facilitate the 
ability to empirically address child behavior problems. The CBCL/6-18 checklist consists 
of 118 items related to child behavior, on a 3-point scale: “0= Not True; 1 = Somewhat or 
Sometimes True; 2 = Very True or Often True.” The CBCL has been used in more than 
1,000 research studies (Achenbach, 2001). Test-retest reliability was .93; inter-parent 
agreement was .76 (Achenbach, 2001). The CBCL/6-18 scoring profile provides raw 
scores, T scores, and percentiles for three competence scales (Activities, Social, and 
School), Total Competence, eight cross-informant syndromes, and Internalizing, 
Externalizing, and Total Problems. Internal consistency for the Internalizing, 
Externalizing, and Total Problems scales was .80, .94, and .94, respectively (Achenbach, 
2001).  
Family Background Information Form 
Key demographic data were collected with the Family Background Information 
Form. The researcher requested information about age, gender, marital status, level of 
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educational attainment, and total number of children to facilitate interpretation of the data 
analyzed. 
Buccal Cell Swabs 
Parents collected buccal (cheek) cell swab samples for his or her child so that 
DNA might be extracted for the analysis of the FMR-1 gene, using a polymerase chain 
reaction procedure.  
Study II 
Revised Biopsychosocial Screening Inventory for Fragile X (RBIPSSI-FX) 
The RBIPSSI-FX is a computerized 49-Item Likert scale-like instrument, 
consisting of five subscales: Developmental milestones, Physical, Social /Behavioral, 
Cognitive, and Biological Parent (see Appendix G). The principal investigator revised 
the BIPSSI-FX in accordance with the outcomes of Study I and the recommendations of 
expert reviewers (Lachiewicz, 2003; Mazzocco, 2003; Scambler, 2003). These revisions 
are discussed in Chapter 4, following the results of the data analyses of Study I. 
Modified Checklist for Autism in Toddlers (M-CHAT) 
The M-CHAT (Robins et al., 2001a), a parent response checklist screening for 
maladaptive behaviors in toddlers, is an extension of the Checklist for Autism in Toddlers 
(CHAT, Baron-Cohen, Allen, and Gillberg, 1992), which was established to detect autism 
at 18 months of age (see Appendix I). The CHAT consists of nine items requiring parent 
response and five items which require a health professional's observation. Baron et al 
randomly selected a group of 18 month olds (n = 50) and group of younger siblings of 
children with autism (n = 41). The following nine areas commonly identified in children 
with autism comprised the questionnaire: play, socialization, motor development, social 
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interest, pretend play, protoimperative pointing, protodeclarative pointing, functional 
play, and joint-attention. The study revealed that key psychological predictors of autism 
at 30 months are evident at 18 months of age. The sensitivity of the CHAT to correctly 
identify autism was 38% and the specificity for identifying childhood autism was 98%. 
Similar findings of the efficacy of the CHAT have been demonstrated in studies of more 
than 16,000 toddlers. (American Academy of Pediatrics Committee on Disabilities, 2001; 
Baird et al., 2000; Baron-Cohen et al., 1996). Furthermore, the CHAT is widely endorsed 
as an entity of screening protocols for toddlers suspected of having developmental delay 
(American Academy of Pediatrics Committee on Disabilities, 2000; Bailey et al., 2001; 
Filipek et al., 2000). 
A major limitation of the CHAT is the required observation of a health care 
professional or human development specialist. The literature is replete with references of 
the pivotal role that parents play in diagnosing developmental disabilities in their child. 
Parents identify key concerns in the child's development several months to years before a 
developmental specialist or health care professional diagnoses the child to have a 
developmental disability (Bailey, 2000; DeGiacomo, & Fombonne, 1998; Siegel et al., 
1988; Young, Brewer, & Pattison, 2003). Consequently, Robins, et al. (2001a) developed 
a parent-completed instrument to screen for autism. 
The M-CHAT (Robins et al., 2001a), consists of 23 yes/no items and was designed 
to evaluate the 9 parent-response items of the CHAT and 21 new items added to broaden 
the symptoms and to identify additional pervasive developmental delays. In an initial 
study, the M-CHAT was used to screen 1,293 children of ages 18 to 30 months. Fifty-
eight were later given a diagnostic developmental evaluation and 39 were diagnosed with 
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a disorder on the autism spectrum. Reliability was determined by computing Cronbach’s 
alpha for the 22-item checklist as well as for the subset of the six most discriminating 
items. Internal consistency was α = .85 for the entire checklist and α = .83 for the six 
critical items that discriminate autistic from non-autistic children. A follow-up study 
found a slightly lower level of internal consistency for the total checklist and the six 
critical items, .76 and .74, respectively (Robins, 2003). 
Criterion validity of the M-CHAT was demonstrated by a Discriminant Function 
Analysis (DFA) of nonautistic and autistic children. The DFA correctly classified 33 out 
of the 38 children with autism and misclassified as autistic 8 of the 1196 children who 
had not received a diagnosis of autism. Sensitivity, specificity, positive and negative 
predictive power were calculated as .87, .99, .80 and .90, respectively. Longitudinal 
studies are being conducted to further evaluate criterion validity of the M-CHAT (Robins, 
2003). The primary investigator obtained permission from the authors to use the M-
CHAT in this study (see Appendix H). 
Primary Caregiver Information Form 
This form requested the following demographic information from parents: race or 
ethnic group, gender, age, relationship to the child, state or province, country, level of 
educational attainment, annual household income, religious affiliations, and source of 
support. The data collected are consistent with those collected in Squire and colleagues' 
(2001) study of the efficacy of a parent-completed tool to identify social and emotional 
problems in young children. 
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Diagnosis Information Form 
This form was used to facilitate placement of the respondent information in the 
most appropriate diagnostic group as well as appropriate exclusion of those who do not 
meet the inclusion criteria of the study (see appendix K). 
Data Analysis Plan 
The six hypotheses were analyzed as follows:  
Hypothesis 1, that the BIPSSI-FX measured FMR-1 gene mutation "at risk” status 
in young children validly, as indicated by concurrent validity with the CBCL and the 
CGSQ-FX (Study I), was evaluated by Pearson's r. 
Hypothesis 2, that the BIPSSI-FX measured FMR-1 gene mutation "at risk” status 
in young children reliably, as indicated by test-retest reliability (Study 1) and internal 
consistency (Study I, Study II), was tested by Pearson's r and Cronbach’s alpha, 
respectively; 
Hypothesis 3, that children with FMR-1 gene mutation scored significantly higher 
on the BIPSSI-FX than children without the gene mutation (Study II), was evaluated by a 
t-Test. The t-test is an appropriate test to answer this hypothesis in that the independent 
variable (presence versus absence of FraX) has only two levels. 
Hypothesis 4, that children with FMR-1 full mutation scored higher on the 
BIPSSI-FX than children who have other types of developmental disabilities (Study II), 
was evaluated using a one-way ANOVA. Although the one-Way ANOVA provides the 
same information as the t-Test, ANOVA is the appropriate statistical test in that this study 
only investigates one independent variable, but more than two group means were 
analyzed. This study used a fixed-effect between-subject design. The level of significance 
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selected for this study is p < .05. This level of significance was deemed appropriate 
because of the cognitive/behavioral nature of the data collected. Because the means of 
three groups were compared in this study, Scheffé post-hoc tests were used for 
comparisons for which samples met the assumption of homogeneity of variance. 
Tamhane post-hoc tests were used in comparisons of samples for which Levine’s test for 
homogeneity of variance revealed significant differences in variance between samples.  
Hypothesis 5, that parents of children with the FMR-1 gene mutation scored 
higher on the BIPSSI-FX Biological Parent Subscale than parents of children without the 
gene mutation (Study II), was evaluated using a t-Test.  
Hypothesis 6, that children with FraX differed from those with autism, PDD, and 
Asperger syndrome more on the BIPSSI - FX than on the M-CHAT (Study II), was 
answered using two independent one-way ANOVAs. 
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CHAPTER FOUR 
 
RESULTS 
 
 Frequencies and means for the demographic data for Study I and Study II were 
presented in Chapter 3. Presented in this chapter are data analyses and interpretations to 
address each of the six hypotheses. 
Hypothesis One 
The BIPSSI-FX will measure FMR-1 gene mutation "at risk” status in young 
children validly, as indicated by concurrent validity with the CBCL and the Consensus 
Questionnaire for Fragile X.  
Study I.  The concurrent validity of the original BIPSSI-FX was assessed by 
comparing the results with those obtained on the Child Behavior Checklist (CBCL) and 
the CGSQ-FX. The validity of the Original BIPSSI-FX was assessed by comparing the 
results with those obtained on the CBCL (Achenbach, 2001). An acceptable level for 
Pearson’s r correlations was set a priori at .70.  
Each subscale of the BIPSSI-FX significantly correlated with the total scale score 
of the CGSQ – FX; however only one subscale, the Social and Behavioral Subscale was 
correlated highly, r = .93, p< .0001. The finding was anticipated in that the Social and 
Behavioral Subscale is an adaptation of the 11 social and emotional items of the      
CGSQ – FX (see Table 4). The BIPSSI-FX however, includes descriptors of the scoring 
continuum. The Developmental Subscale showed a moderate correlation of r = .51 and 
the Cognitive Subscale showed a moderate correlation (r= .53). The construction of the 
BIPSSI-FX is more parallel to the CBCL in consideration of the Social and Behavioral 
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aspects of FX than other subscales of the BIPSSI-FX.  This point could account for the 
lack of correlation of the other four subscales of the BIPSSI-FX to the CBCL.  
 
Table 3 
           Correlations between BIPSSI-FX Time 1, CGSQ-FX, and CBCL 
Variables CGSQ 
Total 
CBCL Internal T 
Score 
 CBCL External  
T-Score 
CBCL Total T 
BIPSSI 
Developmental 
.51* .18 .36 .31 
BIPSSI Physical .19 .25 .14 .18 
BIPSSI Social and 
Behavioral 
.93** .73** .83** .84** 
BIPSSI Cognitive .52** .2 .4* .24 
BIPSSI Biological 
Parent  
.19 .48* .31 .42* 
BIPSSI-FX Total .90** .71** .76** .77** 
*p<.01  **p<.001 
Hypothesis Two 
The BIPSSI-FX will measure FMR-1 gene mutation "at risk” status in young 
children reliably as indicated by test-retest reliability (Study 1) and internal consistency. 
Study I. Data collected from the repeated administration of the BIPSSI-FX in 
Study I were evaluated for test-retest reliability by use of the Pearson’s r correlation 
coefficient with levels set at .70.  
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Table 4 
Test-Retest Reliability Original BIPSSI-FX 
______________________________________________________________________________ 
Time 2      Developmental    Physical  Social        Cognitive     Biological 
                    Behavioral                   Parent 
Time 1  
 
Developmental  .68** .52** .60** .54** .18** 
 
Physical  .58** .69** .38 .33   .10 
 
Social/Behavioral         .49*                    .47* .93** .68** .11 
 
Cognitive                        .66**  .36 .46* .62** .18 
 
Biological 
Parent                       -.30** -.26 .08 -.06             .76*** 
 
Note: N=27 at Time 1 and N=24 at Time1.  *p < .05   **  p< .001 
 
The highest degree of stability over time was manifested in responses to the 
Social and Behavioral Subscale, r= .93, p<. 0001.  A high level of stability was also seen 
in the Biological Parent Subscale, in that the responses from the first testing were highly 
correlated with those of the second testing, r= .76, P. <  .0001. 
Reliability of the Original BIPSSI-FX was further appraised by analyzing the total 
scale and each subscale for internal consistency by the computation of Cronbach’s alpha, 
as is shown below in Table 5 for time 1 and Table 6 for time 2. 
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Table 5 
 
Cronbach’s Alpha for the Five Subscales of the Original BIPSSI-FX – Time 1 (N=27) 
 
 
Subscale     Alpha    Standardized 
          Item Alpha 
______________________________________________________________________________ 
 
Developmental      .81     .82 
 
 
Physical     .28     .36 
 
 
Social- Behavioral        .95     .95 
 
 
Cognitive        .89     .91 
 
 
Biological Parent     .61     .62 
 
 
Total Scale     .91     .92 
 
 
The Cognitive Subscale revealed a high level of internal consistency, alpha = .89. 
However, the elimination of item number one ("has your child ever had placement in 
"gifted" class programs or received information that he or she is unusually bright?") 
would increase the overall scale alpha to .98. None of the other items, if deleted, would 
enhance the overall alpha. The items of the Biological Parent Subscale revealed a 
moderate level of internal consistency, α = .61. Eliminating item 10 (“has anyone in the 
father’s family had mental retardation”) would enhance the alpha to .68. 
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Table 6 
Cronbach’s Alpha for the Five Subscales of the Original BIPSSI-FX – Time 2 (N=23) 
 
Subscale     Alpha   Standardized Item 
         Alpha 
______________________________________________________________________________ 
Developmental                 .78    .78 
 
  
Physical     .29    .34 
 
 
Social- Behavioral        .91    .95 
 
 
Cognitive        .83    .89 
 
 
Biological Parent     .44    .39 
 
 
Total Scale     .94    .94 
 
 
Disclosing the presence of mental retardation in ones’ family tends to be difficult, 
therefore it is highly plausible that item number 10 had an associated social desirability 
aspect. Therefore, the researcher combined items 9 and 10 to address both the mother and 
the father in the revised tool to decrease reluctance of a parent to respond accurately. 
Additionally, items 11 and 12; 6 and 7; along with items 3 and 4 were combined in the 
revised BIPSSI-FX to eliminate the aforementioned social desirability factors. Combining 
these items reduced the problem of social desirability because the respondent may 
respond honestly without having to specifically acknowledge challenges in the 
respondent’s own biological family. The respondent is aware that an honest response 
could be interpreted as reflective of either biological parent’s blood family. Additionally, 
the researcher reworded item 5 in a manner in which both the biological mother and the 
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biological father are addressed. These changes could possibly decrease social desirability 
factors and thereby increase the accuracy of the internal consistency of the Biological 
Parent Subscale. 
Study Two. Data obtained by the Revised BIPSSI-FX were analyzed and evaluated 
for aspects of internal consistency by conducting a Cronbach’s alpha (see Table 7). The 
internal consistency for the Developmental Subscale, Social-Behavioral and Cognitive 
Subscales were acceptable. However, the internal consistency of the Biological Parent 
Subscale was lower than desired. In the SPSS output for Reliability Analysis, the Alpha If 
Item Deleted Scale revealed that deleting item 3 would enhance the Biological Parent 
Subscale internal consistency to .60, which is acceptable. Therefore item 3 “Have any 
women in the birth mother’s blood family or the birth father’s blood family, had cysts on 
the ovaries, cysts removed from the ovaries, or hysterectomy (removal of the uterus)?” 
was deleted from the Biological Parent Subscale of the Revised BIPSSI-FX. However, the 
internal consistency of the Physical Subscale was .43, which is not acceptable. 
Furthermore, the elimination of no item would increase the level of internal consistency 
of the subscale. The researcher considered the level unacceptable; therefore, she 
eliminated the Physical Subscale from the Revised BIPSSI-FX in subsequent analyses. 
 
 
 
  74 
 
 
Table 7 
 
Cronbach’s Alpha for the Five Subscales of the Revised BIPSSI-FX  
 
Subscale     Alpha   Standardized Item 
         Alpha 
______________________________________________________________________________________ 
 
Developmental     .67              .67 
 
Physical     .43    .42 
 
Social- Behavioral        .89    .89 
 
Cognitive        .84     .84 
 
Biological Parent     .60    .58 
 
Total Scale     .90    .88  
 
Hypothesis 3 
Children with FMR-1 gene mutation will score significantly higher on the 
BIPSSI-FX than children without the gene mutation.  
Study Two was conducted to address hypotheses three through six as well as 
some aspects of hypothesis two. A t-Test of the mean scores of children who have the 
FMR-1 gene mutation compared to those who do not, revealed a highly significant 
difference as is depicted in Table 8 below.  
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Table 8 
t-Test of BIPSSI-FXby FMR-1 Gene Status 
 
Gene Status n M SD t df p 
       
FraX-FM 
43 78 12.17  
 
  
 
Non-FraX-FM 
 
282 
 
69.35 
 
14.55 
   
    3.7 323 .000 
       
 
The differences between the mean scores of the children with FMR-1 gene full-
mutation and the children without the gene changes were further analyzed by t-Tests on 
the four subscales of the BIPSSI-FX as is shown in Table 9. Levene’s test for equality of 
variances showed that in two subscales the assumption of homogeneity of variance was 
violated. Therefore, the SPSS computer program adjusted the results shown below to 
account for the lack of homogeneity of variance, as is designated by a superscript. 
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Table 9 
t-Test of BIPSSI-FX Subscales by FMR-1 Gene Status 
 t df p Mean difference 
Cognitive Subscale a 2.87 69.11 .005 2.02* 
Developmental Subscale 4.55 343 .000 2.16** 
Biological Parent a -.67 69.59 .505 -.24 
Social Behavioral Subscale 
 
3.12 330 .002 4.72* 
 
a Equal variances not assumed  * p< .001 **p<. 0001.  
 
The t-Tests revealed that significant differences exist among the children with the 
FMR-1 gene changes, from those without the gene changes. However, this analysis did 
not compare subgroups of children without the FMR-1 gene (e.g., autistic children, 
children with PDD-NOS). Therefore, analyses to detect these differences are addressed in 
the report of results in Hypothesis 4. 
Hypothesis 4 
 
Children with FMR-1 full mutation will score higher on the BIPSSI-FX than 
children who have other types of developmental disabilities. 
The scores of children with FMR-1 full mutation on the BIPSSI-FX were 
compared with those of children who have Down syndrome, autism, PDD-NOS, 
Asperger, and children who have no diagnosed disability (Study II), using a one-way 
ANOVA as is depicted in Table 10 and Figure 1. The dependent variable was total score 
on the BIPSSI - FX and the independent variable was diagnostic group with six levels: 
FraX full mutation, Down syndrome, autism, PDD-NOS, Asperger, and no diagnoses.  
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Since the means of six groups were compared in this study, Scheffe’ post-hoc 
comparisons were conducted to determine differences among groups when the Levene 
test not significant. However, when the Levene test revealed heterogeneity of variance, a 
Tamhane post hoc test was conducted, as this test adjusts for inequality of variance 
among groups. Additionally, the Tamhane post hoc is a more conservative test compared 
to the Dunnett, thus decreasing the likelihood of a Type I error. 
Table 10 
ANOVA on BIPSSI-FX Full Scale Scores by Diagnosis Group 
Diagnostic Group N M Mean Difference SD F 
No diagnosis 33 54.52 23.48*** 11.14  
FraX - full mutation  43 78.00 _____ 12.17  
Autism 84 77.26 .74 9.73  
PDD-NOS 63 76.38 1.62 10.81  
Down 90 61.72 16.28*** 14.15  
Total  70.32   42.49*** 
aScheffe, bTamhane, *p < .05, ** p < .001, *** p < .0001 
 
The mean total scores on the BIPSSI-FX were higher for FraX-FM than those of 
each of the other groups. However, post hoc tests elucidated that BIPSSI-FX scores of the 
FraX-FM group were significantly different only from the normative group and the 
children with Down syndrome. There was no significant difference in overall scores 
between the FraX-FM group and autistic or PDD-NOS groups. The mean BIPSSI-FX 
total scores of the five groups of children are depicted in Figure 1 below.  
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Figure 1 
Graph of BIPSSI-FX Full Scale Mean Scores 
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The children with FraX had the highest mean score followed by children with 
autism. Post hoc analyses indicated that the scores were significantly different only with 
the Down Syndrome group and the group of children with no diagnosed developmental 
delay.  
The difference in the mean BIPSSI-FX scores of the children with FraX-FM from 
children without the gene changes were further analyzed by ANOVA on the four 
subscales of the BIPSSI-FX as is shown below in Tables 11-14 and Figures 2-5. The 
Levene’s test for equality of variances showed that in two subscales the samples 
significantly violated the assumption of homogeneity of variance. Tamhane post hoc tests 
were conducted in those situations to adjust for the lack of homogeneity of variance and 
as is designated by a superscript. 
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Table 11 
ANOVA on BIPSSI-FX Developmental Subscale by Diagnosis Group Compared with 
FraX Full Mutation 
Diagnosis group n M 
Mean 
Difference 
 
SD F P 
No Diagnosisb 34 8.76 5.19*** 2.74  .000 
FraX-FM  46 13.89 ___ 2.86   
Autism a 90 12.1 1.79* 2.77  .027 
PDD-NOS a 65 11.57 2.32** 2.78  .002 
Asperger a 12 9.58 4.31** 3.09  .007 
Down b 78 12.19 1.08 2.65  .448 
Total 345 12.02  3.08 17.92 .000 
aScheffe, bTamhane,*p < .05, ** p < .001, *** p < .0001 
 
The mean BIPSSI-FX Developmental Subscale scores of the five groups of 
children depicted in Figure 2 shows that the children with FraX experienced greater 
delays in achieving developmental milestones than any of the other groups of children. 
Children with no diagnosed disabilities scored lower on the Developmental Subscale than 
any of the other groups of children.  
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Figure 2 
Graph of BIPSSI-FX Developmental Subscale Mean Scores by Diagnosis Group 
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The mean BIPSSI-FX Social and Behavioral Subscale scores of the five groups of 
children depicted in Figure 3 shows that the children with Asperger experienced greater 
social and behavioral challenges than any of the other groups of children. However, the 
mean scores of children with FraX were the next highest.  
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Figure 3 
Graph of BIPSSI-FX Social Behavioral Subscale by Diagnosis Group 
 
 
 
 
 
 
 
 
 
 
 
 
The difference in the mean Social and Behavioral scores of the children with 
FraX-full mutation from the groups of children without the gene changes were further 
analyzed by ANOVA as is shown below in Table 12. Post hoc analyses revealed that the 
parents of a child with FraX-full mutation reported significantly greater social and 
behavioral challenges in their affected child than did the parents of children with Down 
syndrome and those of children with no diagnosed disability. Although the parents of 
children with Asperger appraised their child’s social and behavioral challenges as greater 
than those of the parents of children with FraX-full mutation, the difference was not 
significant. 
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Table 12 
ANOVA on BIPSSI-FX Social Behavioral Subscale by Diagnosis Group Compared 
with FraX-Full Mutation 
Diagnosis group N M 
Mean 
Difference SD F P 
No diagnosis a 33 24.81 9.65*** 6.24  .00 
FX-FM 43 34.47 ____ 8.32  ____ 
Autism 87 34.67 -.20 6.42  1.00 
PDD-NOS 63 34.54 -.08 7.99  1.00 
Asperger 12 39.25 -4.79 9.55  .57 
Down a 94 22.49 11.98*** 7.55  .00 
Total 332 30.36  9.40 40.71 .00 
aScheffe,  * p < .05, ** p < .01, *** p < .001, **** p < .0001 
 
The mean BIPSSI-FX Cognitive Subscale scores of the five groups of children 
depicted in Figure 4 shows that children with autism experienced greater cognitive 
challenges in comparison with children with FraX-full mutation. The scores of children 
with no diagnosed disability were lower than the scores for all other groups of children 
with disabilities. 
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Figure 4 
Graph of BIPSSI-FX Cognitive Subscale Mean Scores by Diagnosis Group 
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The results of post hoc analyses shown in Table 13 revealed that the mean 
Cognitive Subscale scores of the children with FraX-full mutation differed significantly 
from those of children with no diagnosed disability. Additionally, the group of children 
with Asperger showed significantly stronger cognitive abilities than the children with 
FraX-full mutation.  
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Table 13 
ANOVA on BIPSSI-FX Cognitive Subscale by Diagnosis Group Compared with  
FraX–Full Mutation  
 
Diagnosis group N M 
 
Mean 
Difference 
SD F p 
       
No diagnosis b 33 8.85 9.40*** 4.55  .000 
FraX full mutation 45 18.24 _____ 4.21  _____ 
Autism 89 18.89 -.44 3.87  1.00 
PDD-NOS 65 17.55 .69 3.54  .999 
Asperger b 12 14.17 4.08* 3.49  .037 
Down Syndrome 97 15.83 2.41 6.02  .098 
Total 341 16.49  5.38 24.98 .000 
bTamhane,  
* p < .05, ** p < .01, *** p < .001, **** p < .0001 
 
Hypothesis 5 
Parents of children with the FMR-1 gene mutation will score higher on the 
BIPSSI-FX Biological Parent Subscale than parents of children without the gene 
mutation.  
BIPSSI-FX Biological Parent Subscale scores of parents of children with the 
FMR-1 gene mutation were compared with those of parents of children without the gene 
mutation by conducting a t-Test as is shown in Figure 5 and Tables 14 and 15. 
 
Figure 5 
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Graph of BIPSSI-FX Biological Parent Subscale Mean Scores by Diagnosis Group 
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Surprisingly the parents of children with FraX scored lower on the Biological 
Parent Subscale than the parents of children in each of the autism spectrum disorders. 
Furthermore, the scores of the parents of children with no diagnosed disabilities were 
higher than those of the parents of children with FraX. Foster parents were eliminated 
from the study in an effort to prevent the challenge of non-biological primary caregivers 
trying to address questions without adequate knowledge of the child’s biological family, 
but adoptive parents were retained. 
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Table 14 
 
t-Test on BIPSSI-FX Biological Parent Subscale by FMR-1 Gene Status 
 
Gene Status N M SD t  p 
FraX-FM 43 78 12.17  
 
  
Non-FraX-FM 282 69.35 14.55    
    -.67 69.59 .505 
       
 
Table 15 
ANOVA on BIPSSI-FX Biological Parent Subscale by Diagnosis Group Compared 
with FraX Full Mutation 
 
Diagnosis group n M Mean 
Difference 
SD F p 
       
No diagnosis 33 12.27 -.76 3.57  .989 
FraX full mutation 43 11.51 ______ 2.07   
Autism 85 11.78 -.27 2.88  1.00 
PDD-NOS 63 12.83 -1.31 2.79  .093 
Asperger 12 12.17 -.66 3.35  1.00 
Down 90 10.73 .78 2.30  .55 
Total 326 11.72  2.80 4.85 .000 
**** p < .0001 
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There were no significant differences on the mean BIPSSI-FX Biological Parent 
Subscale scores between the parents of children with the FMR-1 gene mutation and those 
of the parents of the children without the FMR-1 gene mutation.  
Hypothesis 6 
 
Children with FraX will differ from those with autism, PDD, and Asperger 
syndrome more on the BIPSSI - FX than on the M-CHAT. The group of children with 
Asperger Syndrome was excluded from the analyses due to a sample size of only n=12. 
Two independent One Way ANOVA’s were conducted to compare the ability of 
the BIPSSI - FX and the M-CHAT to differentiate children with FraX from those with 
autism, and PDD-NOS as is shown below in Table 16. The mean group M-CHAT scores 
are depicted by Figure 6. Total M-CHAT scores are inversely related to the risk for 
autism, whereas BIPSSI-FX scores were designed to be positively related to FraX “risk.”  
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Figure 6 
Graph of M-CHAT Mean Scores by Diagnosis Group 
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Table 16 
 
ANOVA on M-CHAT by Diagnosis Group Compared to ANOVA on BIPSSI-FX by 
Diagnosis Group 
Diagnosis 
group 
 
n 
 
M 
 
SD 
 
Mean Difference 
   
M-CHAT 
 
 
BIPSSI-FX 
 
M-CHAT 
 
 
BIPSSI-FX 
 
 
M-CHAT 
 
 
BIPSSI-
FX 
 
No DX    33 20.52 54.52 4.05 11.14 -2.88* 23.48*** 
FX-FM 43 17.63 78.00 3.38 12.18 ___ ___ 
Autism 83 13.39 77.26 3.38 12.17    4.23*** .738 
PDD-NOS 61 16.33 76.38 4.16 9.73 1.3 1.62 
Down 90 19.28 61.72 4.35 10.81 -1.65 16.28*** 
Total 310 17.03 70.32 4.62 14.65 ____ ____ 
 
     F=33.11*** 
df 4;304 
F=42.48*
**df=4;3
08 
 
 
 The FraX group M-CHAT mean scores differed significantly from those of the 
Autism group. However, although the FraX group scored higher on the BIPSSI-FX than 
the Autism group the differences were not significant. The scores of the No diagnosis 
group on the M-CHAT differed significantly from those of the FraX group, however, the 
magnitude of the differences between these groups was greater on the BIPSSI-FX. 
Furthermore, the mean BIPSSI-FX scores of children with Down Syndrome differed 
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significantly from those of the children with FraX, whereas, this difference was not 
manifested by the M-CHAT mean score. 
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CHAPTER FIVE 
 
DISCUSSION  
 
A discussion of the results of the reliability and validity testing of the BIPSSI-FX 
and the ability of the BIPSSI-FX to differentiate among children with FraX from children 
with other developmental disabilities and children with no diagnosed disability is 
presented in this chapter. The findings of the current study are compared and contrasted 
with previous findings, which are presented under each hypothesis. Explanations of 
unexpected findings as well as limitations of the study are presented. Finally presented 
are research implications.  
Interpretation of Findings 
Hypothesis One 
Hypothesis 1 stated that the BIPSSI-FX would measure FMR-1 gene mutation "at 
risk” status in young children validly, as indicated by concurrent validity with the CBCL 
and the CGSQ-FX. The findings generally supported the potential of the BIPSSI-FX to be 
a reliable and valid screening tool for FraX at risk status. However, the small sample 
small size and the homogeneity of the sampling inhibited the appraisal of the efficacy of 
the tool. This hypothesis was confirmed in that each subscale of the BIPSSI-FX was 
significantly correlated with the total scale score of the CGSQ-FX. However only one 
subscale, the Social and Behavioral Subscale was correlated highly. The researcher 
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anticipated this result, in that the 19-item Social and Behavioral Subscale is an adaptation 
of the 11-item social and emotional subscale of the CGSQ-FX. The BIPSSI-FX however, 
includes descriptors of the scoring continuum to facilitate clarity and consistency in the 
respondents’ interpretation of what constitutes “A little,” “A lot,” or “Not at all.”  
The Social and Behavioral Subscale of the BIPSSI-FX correlated with the CGSQ-
FX and with each CBCL subscale, except for the Externalizing T score of the CBCL. This 
BIPPSI-FX subscale measures behavior associated with children with FraX, which 
includes social withdrawal, anxiety, and depression. These findings concur with those of 
Hessl and colleagues (2001) in that girls with FraX exhibited internalizing behaviors 
(social withdrawal, anxious, and depressed behavior) when they used the CBCL to assess 
internalizing behavior.  
The Biological Parent Subscale of the BIPSSI-FX, which is a measure of the 
parents’ psychological functioning, was moderately correlated with both the internalizing 
T score and the total score for their children on the CBCL. This indicates that the 
Biological Parent Subscale is a potential useful diagnostic tool in the early identification 
of children with FraX. This result is congruent with the results of Hessl et al.’s (2001) 
study of the influence of environmental and genetic factors on behavior problems and 
autistic symptoms in boys and girls with FraX. In their investigation of 80 boys and 40 
girls with FraX full mutation and their unaffected siblings, they found that parental 
psychological problems correlated with the Internalizing and Externalizing Scales of the 
CBCL for boys with FraX.  
The BIPSSI-FX Full Scale was highly correlated with the CGSQ and moderately 
correlated with both the Internalizing Scale and the Externalizing Scale of the CBCL as 
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well as the total CBCL score. According to Carter’s (2003) meta-analytic review of 
various types of reliability coefficients and test types and the recommended standards 
(Pearson’s r Coefficient of .70) the coefficients for the BIPSSI-FX were acceptable, 
therefore, hypothesis one was confirmed.  
Hypothesis Two 
Hypothesis 2 stated the BIPSSI-FX would measure FMR-1 gene mutation "at 
risk” status in young children reliably, as indicated by test-retest reliability and internal 
consistency. The researcher recruited an international sampling of parents from racially, 
geographically, and socioeconomically diverse backgrounds by using a unique sampling 
scheme during the second study. In this study, data were collected by Internet and 
automatically received into an Access database, which resulted in a larger and more 
representative sample in comparison to the sample of the first study. See the detailed 
sample description in Chapter 3. 
A moderate correlation was shown on the Cognitive Subscale of the BIPSSI-FX at 
test retest while the Developmental and the Physical Subscale of the BIPSSI-FX were 
highly correlated at test retest. The correlation between the Physical Subscale of the 
BIPSSI-FX on test retest reliability revealed a slightly higher correlation than the 
correlation on the Developmental Subscale. The correlation of the Biological Parent 
Subscale of the BIPSSI-FX was slightly higher than the previous subscales. Finally, the 
highest degree of stability was manifested in the Social and Behavioral Subscale of the 
BIPSSI-FX.  
These results support hypothesis two in that the scale is stable over time. Test 
retest reliabilities were not conducted on other FraX screening tools, by Teisl and 
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colleagues (1999), Lachiewicz and colleagues (2000), and de Vries and colleagues 
(1996), therefore comparison data are unavailable. However, the reliability of the current 
study is comparable to the test retest reliability of associated parental response tools such 
as the CBCL and M-CHAT, .80 and .76-.72, respectively.  
The reliability of the BIPSSI-FX was further appraised by analyzing each subscale 
and the total score at both the first and repeat administration during Study I and initial 
testing during study II. The level of internal consistency was acceptable both overtime 
within the same sample (Study I) and between samples (Study 1 and Study II). 
Furthermore, the reliability of the current study is comparable to the test retest reliability 
of other checklists for FraX, such as, Maes et al.(2000) .84 for the total checklist and .82 
for the behavioral features.Therefore, hypothesis 2 was confirmed.  
The Social Behavioral Subscale and the Cognitive Subscales of the BIPSSI-FX 
revealed a high level of internal consistency while the Developmental Subscale showed 
an acceptable level of internal consistency. However, the internal consistency of the 
Biological Parent Subscale was questionable and the Physical Subscale had an 
unacceptably low level.  
Perhaps, the subtlety of the physical features of FraX, which has been widely 
reported (Lachiewicz et al., 2000; Bailey, et al., 2002; Hagerman, 2002) contributed to 
the low internality consistency of the Physical Subscale. In boys, specific physical 
characteristics such as an elongated face, large head, and prominent ears are typically 
present by age 8 (Stoll, 2001). The physical characteristics of girls are generally normal, 
although some girls share some of the features with boys, such as a long face and 
prominent ears (Butler, Pratesi, Watson, Breg, & Singh, 1993; Hagerman, 2002). 
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Nonetheless, this researcher, like other researchers attempted to elucidate these subtleties 
in an attempt to facilitate early identification of children with FraX (Lachiewicz et al, 
2000; Hagerman, 2002). Although, physical characteristics are variable in females and in 
prepubertal males (Reiss & Dant, 2003) recent studies have increasingly revealed 
distinguishing physical characteristics of FraX in toddlers (Lachiewicz et al., 2000).  
Hypothesis Three 
Hypothesis 3 stated children with FMR-1 gene mutation would score significantly 
higher on the BIPSSI-FX than children without the gene mutation (Study II). The children 
with the FMR-1 gene mutation scored significantly higher on the BIPSSI-FX Full Scale 
than children without the FMR-1 gene changes; therefore, Hypothesis 3 was confirmed. 
A detailed discussion of the interpretation of these findings is presented in the discussion 
of hypothesis 4. 
Hypothesis Four 
Hypothesis 4 stated that children with FMR-1 full mutation would score higher on 
the BIPSSI-FX than children who have other types of developmental disabilities. Children 
with the FMR-1 full mutation (FraX-fM) scored higher on the BIPSSI-FX than the groups 
of children with other developmental disabilities. The children with FraX had the highest 
mean score followed by children with autism spectrum disorders. The mean BIPSSI-FX 
Full Scale score for the group of children with Down syndrome was the lowest of each of 
the groups of children with diagnosed developmental delay. A Post Hoc test elucidated 
that mean BIPSSI-FX Full Scale score of the FraX-FM group were significantly different 
from only the mean BIPSSI-FX Full Scale scores of the normative group and the group of 
children with Down syndrome. There was no significant difference in overall scores 
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between the FraX-fM group and autism, Pervasive Developmental Disorder-Not 
Otherwise Specified (PDD-NOS), or Asperger groups. Therefore, the BIPSSI-FX 
correlated with Down syndrome, but not with PDD-NOS, autism, or Asperger. This 
finding is consistent with those of other research studies (Rogers,Wehner, & Hagerman, 
2001) in that it is challenging to differentiate the clinical features of young children who 
have diverse autism spectrum disorders. 
However, post hoc analysis revealed the specific subscales of the BIPSSI - FX for 
which the scores indeed differed among children with FraX and those with other autism 
spectrum disorders. The Developmental Subscale score differentiated the children with 
FraX from each of the other autism spectrum groups. The Down Syndrome group was the 
only group of children with diagnosed delays from whom the means scores of the 
children with FraX did not significantly differ. As was depicted in Table 1 in Chapter 
Two, developmental milestones have just begun to emerge in checklists for FraX (Bailey, 
2003). The finding in this study supports the potential benefit of the inclusion of an 
assessment of developmental milestones as a mechanism of differentiating children with 
FraX from children with other autism spectrum disorders.  
 In contrast, the Social and Behavioral Subscales did not differentiate the children 
with FraX from those with autism, Asperger, PDD-NOS, but it did differentiate the 
children with FraX from those with Down Syndrome. The literature is replete with 
examples of the similarities in social, emotional, and behavioral attributes of children 
diagnosed with FraX and those with other autism spectrum disorders (Bailey et al., 2000; 
Bailey et al., 2001a; Denmark et al., 2003; Kau et al., 2004; Rogers, Wehner, & 
Hagerman, 2001). Therefore, the finding of this study concurs with previous studies.  
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 Furthermore, mean Cognitive Subscale scores differentiated children with FraX 
only from the children with Asperger. This finding was expected as most children with 
Asperger have normal cognitive development as opposed to children with Down 
Syndrome and other developmental disabilities. For example, male and female children 
with Down Syndrome and girls and boys with autism have mental retardation, whereas, 
95 percent of males with FraX have mental retardation, but only 50% of females with 
FraX-full mutation have intellectual impairment. However, children with FraX did score 
higher on the Cognitive Subscale than those with Down Syndrome and slightly higher 
than those with PDD-NOS, thus indicating a greater amount of cognitive challenges. It is 
possible that the Cognitive Subscale scores of the children with FraX were influenced by 
the concurrent emotional and social challenges such as attention deficits and anxiety. 
Hypothesis Five 
Hypothesis 5 stated that parents of children with the FMR-1 gene mutation would 
score higher on the BIPSSI-FX Biological Parent Subscale than parents of children 
without the gene mutation (Study II). The scores of parents of children with the FMR-1 
gene mutation were surprisingly lower than the mean score of the parents of each of the 
other groups of parents, with the exception of the parents of children with Down 
Syndrome. This finding is truly serendipitous in that the literature strongly supports the 
items of the Biological Parent Subscale as characteristics seen more commonly in 
biological relatives of children with FraX. Although some parents completed surveys for 
children who were members of diverse diagnosis groups, the researcher took steps as are 
described in Chapters 3 and 4, to ensure that the groups were mutually exclusive.  
A possible explanation for the unexpected result could be that the parents of 
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children with FraX have adapted to a life of chronic stress, thereby minimizing the 
reporting of symptoms. It is also plausible that the responses of parents of children with 
FraX were influenced by a social desirability factor, in that FraX is the only diagnosis of 
those included in this study for which an exact genetic mode of transmission is known, 
except for the rare cases (less than 5 %)of Robertsonian Translocation Down Syndrome 
(Bandyopadhyay, et al., 2003). Having a knowledge that one has transmitted the gene 
responsible for mental retardation in one’s child may engender a feeling of guilt in the 
parent responsible for transmitting the FMR1 gene mutation to the child affected with 
FraX. This phenomenon has been documented in the literature (Braden, 1996) and 
several parents of children with FraX, wrote of feelings of guilt in the comments section 
of the survey. 
Another plausible explanation for the lower scores on the Biological Parent 
Subscale among parents of children with FraX is that it is possible that some of the 
parents were FraX-full mutation carriers and have mental retardation. Previous literature 
has documented the greater tendency of individuals with mental retardation to respond in 
ways which the individuals believe others would desire. According to (Finlay & Lyons, 
2001) self-response questionnaires completed by individuals with developmental 
disabilities are especially vulnerable to contamination of social desirability. Furthermore, 
researchers (Sobesky, Hull & Hagerman, 1992; Sobesky, Pennington, Porter, Hull & 
Hagerman, 1994) have described a tendency among females who have the FraX-FM to 
deny problems even when significant others have documented that the problems actually 
exist. Sobesky et al. (1992), who termed the phenomenon a blinders effect, found in their 
study of females with FraX-FM that these women present their current situations in 
  99 
 
 
simplistic ways and tend to discount previous experiences. According to these 
researchers, this tendency for denial measured by the Lie Scale of the Minnesota 
Multiphasic Personality Inventory (MMPI), makes it difficult to document anxiety or 
depression in women with FraX-FM (Sobesky et al., 1992). 
Hypothesis Six 
Hypothesis 6 stated that children with FraX would differ from those with autism, 
PDD-NOS, and Asperger syndrome more on the BIPSSI - FX than on the M-CHAT 
(Study II). Although the M-CHAT detects children with FraX as well as autism, PDD-
NOS and Asperger, the BIPSSI FX did a better job differentiating the children who had 
no diagnoses and those with Down Syndrome from those with FraX than children with 
autism spectrum disorders. The two independent one-Way ANOVAs indicated that the 
BIPSSI FX in conjunction with the M-CHAT may provide a stronger measure of FraX "at 
risk" than the BIPSSI-FX alone. Therefore, hypothesis 6 is confirmed. 
Limitations 
The potential challenges of the use of parent response measures exclusively for 
screening has limitations, as have been well documented (Squires, et al., 2001). This 
aspect is of particular importance in that the researcher did not control for mental 
retardation in the parents who participated in the study.  
Additionally, the use of Internet as the only data collection medium poses several 
potential threats to external validity (Harris & Dersch, 1999). The use of the Internet 
limited the researcher's ability to control for situational contaminants such as; 
environmental factors (temperature, lighting, time of day) or fatigue of the respondents. 
Furthermore, each of the following factors could have influenced the primary caregiver’s 
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responses: response set-bias, transitory personal factors, lack of instrument clarity, and 
the formatting of the instruments. It is possible that extreme responses, such as 
consistently assigning the most severe or the least severe rating to an item without 
considering the question, influenced the self-reported data in this study. However, it is 
unlikely because the parents volunteer to complete the survey with compensation. 
Transitory personal states such as the caregiver’s fatigue, hunger, anxiety, 
fluctuations in mood, or even the trials of the siblings' mood state may have influenced 
the manner in which the primary caregivers responded. Families of children who have 
developmental delays or disabilities are especially subject to temporary states. The 
literature is replete with information regarding how the various bidirectional effects may 
influence transitory or permanent states of individuals within families in which there is a 
child who has a developmental disability (Burton, 1992; Casper & Bryson, 1998; 
Dowdell, 1995; Gardner, Scherman, Mobley, Brown, & Schutter1994; Schilmoeller & 
Baranowski, 1998; Seamon, 1992; Seligman, 1991). Living with a disabled child 
permanently changes the life of each family member causing transitorily personal states 
or permanent personal changes. Sometimes, the process of the family’s adjustment to a 
child with a disability is very strenuous, long, and difficult. As Perske (1981) posits: 
When a new youngster has a handicap, the family often expends energy beyond 
ordinary. An increased sharpening of wits and widening of hearts becomes 
necessary so that the one with the handicap can be understood, loved, and 
accepted as a member of a close-knit family circle. On the other hand, some 
households become cold towards such a child, and more families change for the 
worse (p. 14). 
 
Instrument clarity. The researcher received e-mail messages from participants 
requesting clarification of the instrument. Additionally, two international participants 
commented in the open-ended sections of the survey that some cultural variants made 
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some sections of the surveys challenging to decipher. Their comments indicate that some 
respondents possibly misinterpreted the directions for the accurate completion of the 
research instruments. Finally, some respondents expressed difficulty in using the calendar 
(formatting issues) to enter the completion date and child’s date of birth. However, many 
respondents rectified this problem by typing the intended information in the open-end 
comments section of the survey. 
Recommendations 
Research Implications 
 This researcher recommends the following to further develop the BIPSSI-FX and 
to evaluate its psychometric properties. 1) Conduct factor analysis of the tool to 
illuminate which items tend to cluster. 2) Collect data on more children with FraX-pM 
and conduct discriminate function analysis to determine which items of the BIPSSI-FX 
best predict FraX – FM and FraX –pM. 3) Analyze the subscales in predicting 
membership in a FraX – FM and FraX - pM group to determine if a combination of 
subscale scores instead of one total scale score is a more valid measure of FraX "at risk" 
status.  
 In addition to further analysis of the psychometric properties, the BIPSSI-FX 
should be revised to enhance the clarity of the items and the descriptors by conducting a 
focus group with parents of children with FraX. Furthermore, the Physical Subscale 
should be revised to include only items that have been found to highly discriminate 
toddlers with FraX from children who do not have the FMR-1 gene mutation when 
analyzing the data for children younger than 84 months of age. This may be 
accomplished by scoring in accordance with age intervals such as accomplished in the 
  102 
 
 
ASQ:  SE (Squires et al., 2001). Alternatively, a method such as that used by Maes et al. 
(2000) in their study of a phenotypic checklist to screen for FraX in males aged 3-51 
years could be employed. This method consisted of adjusting the scoring in cases in 
which there were several responses of “Not applicable” as was found in the responses of 
the parent of an individual would could not speak to items about language.. 
 In addition to changes to the Physical Subscale, and the fore mentioned controls 
for mental retardation in parent respondents, the Biological Parent Subscale should be 
expanded to include an additional item which is believed to have potential in the 
bidirectional identification of children with FraX and adults with FraX-premutation, the 
Fragile X Associated Tremors and Ataxia Syndrome (FXTAS - Greco et al.,2002; 
Hagerman & Hagerman, 2004; Hagerman, Leavitt et al.,2004; Leehey et al.,2003; 
Robinson, 2003).  
Furthermore, after the revisions have been made, the BIPSSI FX should be tested 
on larger samples of children with FraX and other developmental disabilities for whom 
confirmatory diagnostic records are available to the researcher, either directly or through 
a collaborative agreement with clinicians after the revisions have been made. Finally, an 
assessment of an infant or toddler independent of an assessment of the child’s proximal 
environment, the family, is incomplete (Seltzer, Abbeduto, Krauss, Greenberg, & Swe, 
2004; Troost & Filsinger, 1993). Therefore, it is imperative to include a measure of the 
family dynamics in the process of using a screening measure to predict FMR-1 gene 
mutation “at risk” status in young children. The measures of family functioning may be 
profound covariates in the analysis of screening measures for children. 
In conclusion, although the BIPSSI-FX cannot replace essential standardized early 
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assessment tests, it may effectively help parents to articulate concerns about the child’s 
development to professionals. Additionally, the BIPSSI-FX may augment comprehensive 
assessment of infants and toddlers and facilitate the decision of whether or not testing for 
the FMR-1 gene mutation is indicated.  
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APPENDIX A 
 
Biopsychosocial Screening Inventory for Fragile X 
Original Parent Response Version 
 
Directions:  
Please mark with an “X” the box that best describes the child, “A lot”, “A little” ”not at 
all” or “N/A if the item does not apply to child.  The last part “Biological parent” should 
be answered with the parent of the child in mind. 
Additional information is provided in some of the boxes to help to make the desired 
choice clear. 
 
Number (last four digits of the Social Security Number)______________________________ 
 
Date of Form Completion:_______________________________ 
 
 
Child’s Date of Birth: _______________________________  
  
 
DEVELOPMENTAL MILESTONES     
1.   How old was your child when 
he/she could sit without support?   
 
Older than 9 
months 
Older than 7 months 
Younger 
than 7 
months 
 
 
 
 
2.   How old was your child when 
he/she began walking well?   
Older than 20 
months 
Older than 14 months 
 
Younger 
than 14 
months 
 
 
3.   At what age did your child first say 
a  first word? 
 
Older than 18 
months                  
Older than 12 months          
Younger 
than 12 
months 
 
4.   At what age did your child first 
wave “bye-bye?” 
Older than 14 
months 
 
Older than 9 months, but 
earlier than 14 months  
 
 
Younger 
than 9 
months 
 
5.   At what age did your child first 
respond to her or his name? 
 
Older than 10 
months 
 
 
Older than 7 months, less 
than 10 months 
Younger 
than 7 
months 
 
6.   At what age was your child toilet 
trained?( urine and BM, with not more 
than 3 accidents while awake in one 
year) 
 
 
5 years or older, or 
is not now toilet 
trained 
 
Older than four years but 
less than five 
Younger 
than four 
years 
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PHYSICAL 
 
A Lot A Little 
Not at 
All N/A 
1.   Does your child have low muscle 
tone/ muscle 
weakness? 
    
2.   Does your child have any seizures? 
2 or more seizures 
and takes  medicine 
for seizures 
At least 1 seizure   
3.   Has your child ever had frequent 
ear infections (more than 3 per year)? 
 
More than 3 per 
year 
 
 
At least 2 per year, but at 
least 1 
 
  
4. Has your child ever had frequent 
colds or nasal infections? 
 
At least 3 or more 
per year 
At least 2 per year, but at 
least 1 
 
  
5.  Has your child ever had cleft lip, 
cleft palate or an arched palate (top of 
the inside of the mouth). 
    
Social / Behavioral A Lot  A Little 
Not at 
All 
N/A 
1. Has your child ever avoided looking 
others in the eye? 
    
2.   Has your child had problems at 
home or school? 
    
3.   Has your child had emotional 
problems? 
    
4.   Has your child had behavioral 
problems? 
    
5.   Has your child ever had treatment 
for emotional or behavioral problems? 
3 or  
more visits,  
at least one 
hospitalization  
 
2 visits or  
less, no  
hospitalizations 
  
6.   Has your child ever taken 
medication for emotional or behavioral 
problems?   
2 or more 
medicines for 
longer than 1 
month 
1 medicine or if 
more, for less than 
1 month 
  
7.   Has your child ever had difficulty 
keeping his or her attention focused? 
    
 
8.   Has your child ever had problems 
talking with people he or she does not 
know? 
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SOCIAL/BEHAVIORAL A Lot A Little 
 
 
Not at 
All 
 
N/A 
9.  Has your child ever had problems 
playing with people he or she does not 
know? 
    
10.  Has your child ever had problems 
with sad or depressed mood? 
    
11.  Has your child ever had problems 
with nervousness or anxiety? 
    
12.   Has your child ever had a problem 
with hurting himself or herself by head 
banging or biting hands, arms or other 
parts of their body? 
    
13.   Has your child ever had problems 
with picking at his or her skin or biting 
fingernails?      
    
14.   Has your child ever had problems 
with making the same movements over 
and over. 
     
15.   Has your child ever had problems 
with saying the same word or phrase 
over and over? 
    
16.   Has your child ever had problems 
with talking about the same subject 
over and over? 
 
    
17.  Has your child ever had problems 
falling asleep or staying asleep?              
5-7 nights per  
week 
 
1-4 nights per  week 
 
 
  
18.  Has your child ever had an upset or 
disturbed response to soft or light touch 
or attempted to cover himself or herself 
with heavy objects such as sofa 
cushions, a mattress, blankets, beanbag 
chairs, etc.?  
 
    
19. Have you every heard your child 
talking to him or herself or making 
humming sounds? 
 
Almost daily Less than twice a week. 
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COGNITIVE A Lot A Little 
 
Not at 
all 
 
N/A 
1.  Has your child ever placement in 
“gifted” class programs received or 
received information that he or she is 
unusually bright?  
In gifted and 
talented class for 1 
year or more 
Not in a gifted and 
talented program, but 
receives “only A’s and 
B’s on progress reports. 
          
 
2.   Has your child ever had any speech 
problems?  
 
    
 
3.   Has your child ever received speech 
therapy? 
 
    
 
 4. Has your child ever had any 
language problems? 
 
    
 
5.   Has your child ever received 
language therapy? 
    
  
 6.   Has your child ever had any 
learning problems?     
 
7.   Has your child ever had problems 
such as a learning disability, being a 
slow learner, or with mental 
retardation? 
    
 
8.   Has your child ever attended 
special classes or preschool or received 
tutoring? 
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BIOLOGICAL PARENT A Lot A Little 
Not at 
All 
 
N/A 
 
 
1.   Have you or your mother, sisters or 
aunts had early menopause? 
 
Before age 35 
yrs 
 
Before age 40 yrs; 
older than 35   
2.  Have you or your mother, sisters or 
aunts had cysts on the ovaries? 
Both ovaries 
or more than 
one time 
One ovary, no 
more than one 
time 
 
  
3.   Did the mother (child’s mother) 
ever have problems with feeling 
depressed or nervous before 
becoming a parent? 
 
Has received 
hospital 
treatment 
Has received 
therapy, but not 
hospital treatment 
  
4.  Did the father (child’s father) ever 
have problems with feeling 
depressed or nervous before 
becoming a parent? 
 
Has received 
hospital 
treatment 
Has received 
therapy, but not 
hospital treatment 
  
5.  Have you or your mother, sisters,        
     or aunts had problems with         
     stopping activities or insisting on    
    doing things exactly a certain way? 
 
Has caused 
problems with 
work, family 
or friends 
 
Bothersome to 
self, but has not 
caused problems 
  
6. Has the mother had problems with 
drinking too much or problems with 
using other drugs, those prescribed 
either by a health care provider or those 
not prescribed? 
  
Has caused 
problems with 
work, family 
or friends 
Bothersome to 
self, but has not 
caused problems 
with others 
  
  
 7.  Has the father had problems with 
drinking too much or problems with 
using other drugs, either those 
prescribed by a health care provider or 
those not prescribed? 
 
 
Has caused 
problems with 
work, family 
or friends 
Bothersome to 
self, but has not 
caused problems 
with others 
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BIOLOGICAL PARENT A Lot A Little 
Not at 
All 
 
N/A 
 
 
8.   Have any other family members 
had problems with drinking too much 
or problems with using other drugs, 
either those prescribed by a health care 
provider or those  not prescribed? 
Mother or 
Father 
Grandparent Aunt, 
Uncle or cousin   
9.   Has anyone in the mother’s (child’s 
mother) family had  mental retardation? 
Mother, 
father, 
grandparent, 
brother or 
sister 
Aunt, Uncle or 
cousin   
10.  Has anyone in the father’s (child’s 
father) family had mental retardation? 
Mother, 
father, 
grandparent, 
brother or 
sister 
Aunt, Uncle or 
cousin   
11.   Has the mother (child’s mother) 
had problems with doing math? 
Influenced job 
choices 
 
Did not influence 
job choices 
  
12.   Has the father (child’s father) had 
problems with doing math? 
Influenced job 
choices 
Did not influence 
job choices 
 
  
 
Scoring: 
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APPENDIX B 
Screening Questionnaire for Fragile X Syndrome 
 
CONSENSUS GROUP SCREENING QUESTIONNAIRE 
 
Purpose:  To increase the recognition of the affected neurobehavioral states in fragile x syndrome and other genetic 
conditions. 
 
Directions:  The questionnaire is designed to be given as a brief interview.  The informant will usually be the patient( begin 
questions with “Have you…”). In the case of children or individuals with developmental disability, parent, guardian or other 
caregivers should provide the information 
(begin questions with “Has( name”). 
 
Please complete one questionnaire for each family member. 
Patient Name/Number: ____________________________Date of Birth______________ 
Sex__________ Date: _______________ 
 
Informant(s): __________________________Relationship to Patient: _________________________ 
Interviewer:_________________ 
 
History-Cognitive   Circle One Answer  History-Behavior   
Circle One Answer 
 
1) Ever had any learning, speech or      Yes       No   No Info 1) Ever had problems at home  Yes   No  No  Info 
        language problems?     or school? 
 If yes, describe____________________________________          If yes, describe________________________________ 
________________________________________________ ____________________________________________ 
_________________________________________________         _____________________________________________ 
    
2) Ever attended special classes           Yes       No   No Info  2)  Ever had any emotional or  Yes       No   No Info 
or  preschool; received tutoring:   or behavioral problems? 
had math or reading problems? 
If yes, describe___________________________________ If yes, describe________________________________ 
________________________________________________  _____________________________________________ 
  
3) Ever received speech or       Yes       No   No Info 3)   Ever taken medications for   Yes       No  No Info 
Language therapy?           emotional or behavioral problems? 
 If yes, describe____________________________________ If yes, describe________________________________  
________________________________________________ _____________________________________________ 
_________________________________________________  _____________________________________________
     
4) Ever had problems such as a learning  Yes       No   No Info       4) Ever received treatment    Yes  No No Info 
disability; being a slow learner,    for emotional or behavioral  
or mental retardation?    problems? 
If yes, describe________________________________ ____ If yes, describe________________________________ 
_________________________________________________   _____________________________________________
     
5) Ever had an achievement or IQ test?  Yes       No   No Info    5)  Ever had difficulty with: 
If yes, brief description of reason for test                                       a) keeping attention focused?         Yes  No    No Info 
And estimate date and site of testing(to   b) avoiding  looking others in         Yes  No   No Info 
Obtain records)__________________________       the eye? 
 ________________________________________________ c)discomfort socializing with           Yes   No   No Info 
 ________________________________________________      people you don’t know? 
       d) down or depressed mood?          Yes   No   No Info 
       6) (For Adults Only) How many years of   e) nervousness or anxiety?      Yes   No   No Info 
 schooling ( education) have you had? ____________  f) injuring yourself?                        Yes   No   No Info 
       g)making the same movements      Yes   No   No Info 
       7)         Highest level of education achieved? ____________     over and over?    
                        h) saying the same word or phrase Yes  No  No Info 
       over and over? 
      8) (For Adults Only) Occupation: _______________________ i) talking about the same subject   Yes    No   No Info 
          over and over again? 
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Summary – If there is indication of cognitive/learning or behavioral/psychological problems, the following recommendations 
are made: 
 
Recommendations for cognitive (IQ) testing:  If available, obtain records of prior testing.  If no prior records, referral for 
cognitive testing should be made for all patients whenever possible, but particularly for patients suspected of having a learning 
problem. 
 
Overall Cognitive Function:  Normal_____ Borderline IQ  ________Mild Retardation_______Moderate Retardation 
_______ 
 
Severe-Profound Retardation ______ IQ______ Name of IQ Test________________  
 
Recommendation for behavioral assessment:  At time of visit parent should complete the Child Behavioral Checklist (CBCL)1 
for any child ages 2 to 16 with no evidence of mental retardation. Factor scores from the CBCL will indicate level of 
hyperactivity, depression and social deficits.  Each parent should also complete the Hopkins Symptom Checklist (HSCL)2  
 
Child Behavioral Checklist available from T.M. Achenbach, Center for Children, Youth & Families, University of Vermont, 1 
South Prospect St. Burlington, VT 05401: 2 HSCL available from Journal of Affective Disorders 1: 9-24. 1979 
 
 
 
 
Used with the permission of coauthor Michelle Mazzocco
  
134 
 
 
APPENDIX C 
Study I - Institutional Review Board Approval 
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APPENDIX D 
 
OKLAHOMA STATE UNIVERSITY 
INFORMED CONSENT FORM 
 
 
Title of the Project: PILOT STUDY OF THE EFFICACY OF SCREENING TOOL 
IDENTIFICATION OF YOUNG CHILDREN AT RISK FOR THE FMR-1 GENE 
MUTATION 
 
AUTHORIZATION 
 
 
I,                                              _______, agree for my child________________________ to 
participate as a volunteer in a study as a part of a research program of Oklahoma State University, 
under the supervision of the College of Human Environmental Sciences faculty members. 
 
DESCRIPTION OF RESEARCH AND PURPOSE 
 
I understand that the purpose of the research is to investigate the effectiveness of a screening tool 
to identify a gene difference in young children that sometimes causes problems with behavior and 
learning. I understand that the research will include my completion of brief questionnaires and the 
collection of a buccal (cheek) cell swab sample from my child. 
 
PROCEDURES 
 
As a participant in this study, I understand that the following procedures are involved:  
 
1.  Each parent or legal guardian (the primary caregiver) will complete the Consensus Group 
Fragile X Screening tool with this or her child who is participating in the research study 
in mind. 
 
2 Each parent or legal guardian (primary caregiver) will complete The Biopsychosocial 
Screening Inventory for Fragile X (BIPSSI-FX) with the child who is participating in the 
research study, in mind. 
 
3. Each parent or legal guardian (the primary caregiver) will fill-out regarding the child who 
is participating in the research study, The Carey Temperament Scales Toddlers 
Temperament Scales(for children 12 to 24 months) and the Infant/Toddler Symptom 
Checklist ( for children 12 months to 30 months), The Child Behavior Checklist Ages 1-
1/2 years to 5 years (for children 25-71 months) or The Child Behavior Checklist Ages 6-
18 (for children older than 72 months). 
 
4. Each parent or legal guardian (the primary caregiver) will complete, the Family 
Background Information Form. 
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5. Each parent or legal guardian (the primary caregiver) will participate in a loosely 
structured questionnaire concerning his or her child who is participating in the research 
study, family supports and stressors and access to community services. 
 
6. Each parent or legal guardian will collect a swab (light brushing) of the inside of the 
child’s mouth in the cheek area.  This procedure should be done immediately before 
brushing the child’s teeth. The swab used to collect the sample is similar to a Q-tip swab.  
This swab is longer than the usual Q-tip swab but is controlled in similar manner as a 
toothbrush. A child who usually brushes his or her teeth without help may collect the 
swab sample under the parent’s supervision. The swab will be placed in the container 
provided by the researcher, labeled with using the last four digits of the child’s social 
security number and mailed by the parent or the researcher in the prepaid and addressed 
express mail envelope to the laboratory where the sample will be tested. 
 
7. Each parent, if desired, will be told by a research assistant or genetic counselor, by 
telephone and in writing of the preliminary results of the cheek cell swab samples. 
Referral information regarding more definitive testing and counseling will be provided by 
the research assistant or genetic counselor.   Additionally, a summary of the findings of 
each of the questionnaires/assessment tools completed, will be provided to the parent, if 
desired.  In addition, if desired, each parent will be informed in writing of the general 
findings of the study.  The principal investigator, Vanessa  Johnson Thomas, will 
remain unaware of the identity of the DNA sample results as well as the identity of the 
questionnaire results.  
 
Do you want to be told the results of the genetic test? 
   [   ] Yes     [  ]No 
 
Additional tests:  It is standard practice for laboratories to store samples that are left over after 
testing. The samples often can be used for up to 5 to 10 years after collection.  The researchers 
are asking your desires concerning the results of any future genetic or medical testing.  Will you 
allow us to test any samples left over from your buccal (cheek) cell sample? 
 
   [   ] Yes     [  ]No 
 
  Do you want to be provided with a summary of the results of the questionnaires? 
 
   [   ] Yes     [  ]No 
 
Potential Risks 
 
I understand that there are no known risks to my child or me by participating in this research.  If 
my child is identified as possibly having the gene mutation, this information may produce 
unpleasant emotional responses for my family and me.  I understand that genetic counseling 
referrals and counseling from a qualified health professional is available to me, my child and 
other family members, if desired. Also, information regarding appropriate community agencies 
will be available to me.  
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If you answered “yes” to any of the above questions, and important in genetic or medical 
information about you or your family is found, a genetic counselor will first re- inform you of the 
potential risks and benefits of telling you this information.   
 
POTENTIAL RISKS 
 
These risks include the possibility that you or your child have a genetic or medical 
abnormality that was previously unknown to you and that may be important to your 
health, or to the health of your children, future children, or extended family, and that also 
could impact matters such as eligibility for health and life insurance.  Only after you have 
had a chance to review this information again, will the genetic counselor or research 
assistant reveal to you the preliminary results of the genetic testing. 
 
BENEFITS 
 
There is no direct benefit for you or your child.  The possible general benefit to science resulting 
from participating in this study includes adding to the knowledge about ways in which potential 
behavioral and developmental challenges may be identified early, easily and inexpensively.   
 
The possible benefits of participating in this research study's may be that early involvement 
services and programs for the child may be more easily available because of the 
identification of gene changes that are often associated with behavioral and 
developmental challenges. In addition, various related treatments are being researched 
nationally and internationally and progress is being made toward decreasing challenges 
associated with having this gene change that causes Fragile X Syndrome.  Moreover, 
research currently supports the use of certain medications, educational strategies and 
other therapeutic measures that seem to work better than others do in treating the 
symptoms related to Fragile X Syndrome. Knowledge of your child’s FMR-1 gene status 
may help you and your child to make important family decisions.  
 
THE RESEARCHERS CANNOT GUARANTEE ANY BENEFIT TO YOU OR YOUR 
CHILD FROM PARTICIPATION IN THIS STUDY. 
 
CONFIDENTIALITY 
I understand that the information obtained from my child and me will be kept 
confidential, using the following methods:  (1) all data collected will be identified by 
using a code number assigned to my child (the last four numbers of the social security 
number), (2) the list of the codes will be kept under lock and key, with access to no one 
but the research assistant and the laboratory personnel, the principal investigator,(3) 
Vanessa Johnson Thomas will NOT have access to the identifying code sheet (4) study 
findings will be reported as grouped data in a way that no individual may be identified. 
 
I understand that my child and I are free to refuse to participate in any part of the study at 
any time without bias and unfair treatment to either of us. Additionally, the research will 
be explained to my child and the researchers will attempt to obtain assent (agreement to 
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participate) from my child. I understand that my child and I are free to stop participating 
in the study at any time without penalty or  bad treatment.  I understand that by agreeing 
to participate in this research and by signing this form, I do not give up any of my legal 
rights. 
 
If  I have any questions about the study, or need to report any unpleasant effects from the 
research procedures, I will contact;  Patricia Self, Ph.D.,  the supervising professor at 
Oklahoma State University Department of Human Development and Family Science, at 
(405) 744-8348, during the workday or Vanessa Johnson Thomas, doctoral student, 
Oklahoma State University Department of Human Development and Family Science at  
(918) 295-7858 or (918) 850-5279 or vjthomasrn@aol.com during the day, evenings and 
weekends. 
 
If I have questions about my rights as a research participant, I will contact: Sharon 
Bacher, Institutional Review Board Executive Secretary, Oklahoma State University, 203 
Whitehurst, Stillwater, OK  74078. Telephone: 405- 744-5700. 
 
I have read this consent document.  I understand its contents, and I freely consent for my 
child to participate in this study under the conditions described here.  I will receive a 
copy of this consent form. 
 
Date:                                                               Time:                                                  (a.m./p.m.) 
 
                  
Name (printed)   Signature                                                                                               
 
             
Signature of person authorized to sign for subject, if required 
 
 
Witness(es) if required:                                                                                                                   
 
                                                                                                                     
 
 
I certify that I have personally explained all elements of this form to the subject or his/her 
representative before requesting the subject or his/her representative to sign it. 
 
 
 
Signed:              
         Project director or authorized representative
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OKLAHOMA STATE UNIVERSITY 
 
INFORMED ASSENT 
 
We want to learn how well a form can help us to find out information about the way a child 
acts and learns.  We will ask your parent to fill out papers that ask questions about the way 
you do things. 
 
The test will not hurt you.  We will ask your parent to help you wipe inside your cheek with 
a swab.  This will feel like placing a toothbrush in your mouth or rubbing your tongue 
against the inside your cheek. 
 
We hope to learn a lot, about how our paper and pencil test will help us get the information 
that the swab gives.  Taking part in this test probably will not help you directly. 
 
If you agree to this test, please sign your name on the line below.  
 
If you change your mind about having the test done, anytime, you may stop the test or 
refuse to begin. If you decide not to take part in the test, we will not treat you differently 
than if you had done the test. 
 
 
    
_________________________________  _________________________ 
Child’s Name       Date 
 
 
_________________________________  _________________________  
Researcher       Date: 
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APPENDIX E  
 
Study II – Institutional Review Board Approval 
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APPENDIX F  
 
Study II - Informed Consent – How to Participate 
 
HOW TO PARTICIATE 
Purpose of the Study 
The purpose of this research is to gather information that may be helpful in developing an 
effective parent completed survey that may be used by parents to help check their child’s 
development.  The forms are used for research purposes only and should not be used to 
measure your child's development.  However, research is a major step toward treatments 
and cures.  
 
Please contact your physician or other child development professional if you have concerns 
about your child's development. 
 
If you have one or more children between the ages of 12 months to 18 years of age whom a 
health care professional has diagnosed to have: 
    Autism  
  Pervasive Developmental Disorder (PDD) 
  Asperger Syndrome  
  Down Syndrome 
  Fragile X Syndrome 
  Fragile X Premutation Carrier 
  No disabilities DNA tests have ruled-out Fragile X Syndrome. 
 
We invite you to participate in our study. 
 
Your Consent and Rights 
All of your information will be kept private and information about the study will be reported 
only in grouped information, using computer assigned numbers and no names.  E-mail addresses 
will not be shared with any other group or person and will NOT be stored. 
 
If you have any questions or concerns about the surveys, or wish to report any adverse 
effects from the research procedures, you may contact Patricia Self, at (405) 744-8348, 
during the workday or Vanessa Johnson, at (918) 295-7858 or (918) 638-7858 or 
tveness@okstate.edu during the day, evenings and weekends. 
 
If you have questions about your rights as a research participant, you may contact: Dr. Carol 
Olson, IRB, Oklahoma State University, 203 Whitehurst, Stillwater, OK 74078.  Phone: 405- 
744-5700. 
 
 
By completing the surveys and returning them, you are agreeing to participate in this 
research. 
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Instructions 
The following instructions are to assist you to complete the surveys on the computer.   
1.      Please select the translation of the website and surveys that you wish to use by 
clicking the language in the translation drop box at the bottom of the first page. 
2.       There are four brief surveys to complete: The Primary Caregiver Background, 
the Diagnosis Form, The Biopsychosocial Screening (BIPSSI), and the M-CHAT. 
Please complete each survey using the scroll-down bars and checking the box(s) 
that indicates your selection. When you are finished with each survey click on the 
“next form” button and it will take you to the next survey. By completing these 
surveys and electronically submitting them, you are agreeing to participate 
in this research.  
3.      Please read each question carefully, but quickly. Do not spend too much time 
trying to answer one question. There are no right or wrong answers. 
4 .   If you have more than one child who meets the conditions for the study listed 
above, please complete the four surveys for the first child then return to the How 
to Participate page and begin the surveys for the next child and so on. 
5. We appreciate you participating in this study and helping professionals working 
with children to gain helpful information. 
Thank you very much! 
Start Survey  
 
Choose a Language
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APPENDIX G 
 
BIPSSI-FX 
Revised Parent Response Version 
 
Directions:  
Please mark with an “X” the box that best describes the child, “A lot,” “A little,” “not at 
all” or “N/A” if the item does not apply to child.  The last part “Biological parent” should 
be answered with the parent of the child in mind. 
Additional information is provided in some of the boxes to help to make the desired 
choice clear. 
Date of Form Completion:_______________________________ 
 
 
Child’s Date of Birth: _______________________________  
 
 
  
     
1.   How old was your child when he/she 
could sit without   
support?   
 
Older than 9 
months Older than 7 months 
Younger 
than 7 
months 
 
 
 
 
2.   How old was your child when he/she 
began walking well?  
Older than 20 
months 
Older than 14 
months 
 
Younger 
than 14 
months 
 
 
3.   At what age did your child first say a 
first word? 
 
Older than 18 
months                  
Older than 12 
months                        
Younger 
than 12 
months 
 
4.   At what age did your child first wave 
“bye-bye?” 
Older than 14 
months 
 
Older than 9 
months, but earlier 
than 14 months  
 
 
Younger 
than 9 
months 
 
5.   At what age did your child first 
respond to her or his name? 
 
Older than 10 
months 
 
 
Older than 7 
months, less than 10 
months 
Younger 
than 7 
months 
 
6.   At what age was your child toilet 
trained?( urine and BM, with not more 
than 3 accidents while awake in one year) 
 
 
5 years or older, or 
is not now toilet 
trained 
 
Older than four 
years but less than 
five 
Younger 
than four 
years 
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A Lot A Little 
Not at 
All N/A 
 
1.   Does your child have low muscle 
tone/muscle weakness? 
 
    
2.   Does your child have any seizures? 
2 or more 
seizures and 
takes  
medicine for 
seizures 
At least 1 
seizure 
  
3. Has your child ever had frequent colds 
or nasal infections? 
 
More than 3 
per year 
 
 
At least 2 per 
year, but at 
least 1 
 
  
4. Has your child ever had cleft lip, cleft 
palate or an arched palate (top of the 
inside of the mouth)? 
At least 3 or 
more per 
year 
 
At least 2 per 
year, but at 
least 1 
 
 
  
 
5.  Has your child ever had frequent ear 
infections (more than three per year)? 
 
    
 
6. Does your child have problems with his 
or her eyes?   
 
    
 
7. Does your child have a long face and / 
or long ears?  
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 A LOT A Little 
 
Not at 
all 
N/A 
 
1. Has your child ever avoided looking 
others in the eye? 
    
2.   Has your child had problems at home 
or school? 
    
3.   Has your child had emotional 
problems? 
    
4.   Has your child had behavioral 
problems? 
    
5.   Has your child ever had treatment for 
emotional or behavioral problems? 
3 or  
more visits, at least 
one hospitalization  
 
2 visits or  
less, no  
hospitalizations 
  
6.   Has your child ever had difficulty 
keeping his or her attention focused? 
    
7.   Does your child talk with people he or 
she does not know or has your child done 
this in the past? 
    
8.  Has your child ever had problems 
playing with people he or she does not 
know? 
    
9.  Has your child ever had problems with 
sad or depressed mood? 
    
10.  Has your child ever had problems 
with nervousness or anxiety? 
    
11.  Has your child ever had a problem 
with hurting himself or herself by head 
banging or biting hands, arms or other 
parts of their body? 
    
12.  Has your child ever picked at his or 
her skin or bit hands or fingers to the point 
of injuring self? 
    
13.  Does your child make the same 
movements over and over, such as 
rocking, twirling around, or clapping 
hands or has your child done this in the 
past? 
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 A LOT A Little 
 
Not at 
all 
N/A 
14.  Has your child ever had problems 
with saying the same word or phrase over 
and over? 
    
15.  Has your child talked about the same 
subject over and over with, the child to the 
point of development making it hard to 
hold a conversation with him or her? 
    
16.  Has your child ever had problems 
falling asleep or staying asleep? 
5-7 nights 
per  week 
 
1-4 nights 
per  week 
 
 
  
17.  Has your child ever had an upset or 
disturbed response to soft or light touch or 
attempted to cover himself or herself with 
heavy objects such as sofa cushions, a 
mattress, blankets, beanbag chairs, etc.?  
    
18. Have you every heard your child 
talking to him or herself or making 
humming sounds? 
 
Almost daily 
Less than 
twice a week. 
 
 
 
 A LOT A Little 
 
Not at 
all 
N/A 
1.  Has your child ever placement in 
“gifted” class programs received or 
received information that he or she is 
unusually bright?  
In gifted and 
talented class 
for 1 year or 
more 
Not in a 
gifted and 
talented 
program, but 
receives 
“only A’s 
and B’s on 
progress 
reports. 
              
2.   Has your child ever had any speech 
problems?  
    
3.   Has your child ever received speech 
therapy? 
    
4.   Has your child ever had any language 
problems? 
    
5.   Has your child ever received language 
therapy? 
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6.   Has your child ever had any learning 
problems? 
    
7.   Has your child ever had problems such 
as a learning disability, being a slow 
learner, or with mental retardation? 
    
8.   Has your child ever attended special 
classes or preschool or received tutoring? 
    
 A Lot A Little 
Not at 
All N/A 
1.   Have you or your mother, sisters or 
aunts had early menopause (“going 
through the change of life”)or premature 
ovarian failure? 
 
Before age 35 yrs 
 
Before age 40 yrs; 
older than 35   
2.  Have any women in the birth father’s 
blood family had early menopause (“going 
through the change of life”) or premature 
ovarian failure? 
Both ovaries or 
more than one time 
One ovary, no more 
than one time   
3.  Have any women in the birth mother’s 
blood family or the birth father’s family 
had cysts on the ovaries, cysts removed 
from the ovaries, or hysterectomy 
(removal of the uterus)? 
    
4.   Did the mother (child’s mother) ever 
have problems with feeling depressed 
or nervous before becoming a parent? 
Has received 
hospital treatment 
Has received 
therapy, but not 
hospital treatment 
  
5.  Did the father (child’s father) ever have 
problems with feeling depressed or 
nervous before becoming a parent? 
    
6.   Is it or has it been hard for anyone in 
birth mother’s blood family or birth 
father’s blood family to stop activities 
(such as, hand washing, checking locks, 
worrying, refusing to throw items away, 
computer use, watching television) or 
insist on doing things or having things 
done perfectly or exactly a certain way? 
Has caused 
problems with 
work, family or 
friends 
Bothersome to self, 
but has not caused 
problems 
  
7.   Has the birth mother or the birth 
father, now (or in the past) drank too much 
alcohol, used too many drugs, or used 
drugs too often, either those prescribed by 
a health care worker or those not 
prescribed? 
Has caused 
problems with 
work, family or 
friends 
Bothersome to self, 
but has not caused 
problems with 
others 
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8.   Has anyone in the birth mother’s blood 
family or the birth father’s blood family 
had mental retardation/developmental 
disabilities, autism, Asperger Syndrome or 
Fragile X Syndrome? 
Has caused 
problems with 
work, family or 
friends 
Bothersome to self, 
but has not caused 
problems with 
others 
  
9.   Has the birth mother (child’s mother) 
or birth father (child’s father) had 
problems doing math? 
    
 
Scoring:   
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APPENDIX H 
 
Permission to Use the M-CHAT 
 
Subj: RE: Permission to use M-CHAT 
Date: 6/4/2003 7:02:31 PM Central Daylight Time 
From:    fein@uconnvm.uconn.edu (Dr. Deborah Fein) 
To:    Vjthomasrn@aol.com 
CC:    drobins@hp.ufl.edu (Diana Robins), pamdixon2001@yahoo.com (Pam Dixon) 
Dear Vanessa. Thanks for your message. I' m not sure I understand your research question #4, 
but it sounds like a worthwhile project. You have permission to use the M-CHAT in your project. 
You can reprint it yourself from the JADD article, or we can send you a hard copy, which you can 
then copy. If you’d like the latter, please e-mail pamdixon2001@yahoo.com and ask her for one. 
Thanks - Deborah Fein----- 
 
Original Message----- 
From: Vjthomasrn@aol.com [mailto:Vjthomasrn@aol.com] 
Sent: Wednesday, June 04, 2003 6:45 PM 
To: barton@psych.psy.uconn.edu; fein@uconnvm.uconn.edu 
Subject: Permission to use M-CHAT 
 
 
 
 
 
June 3, 2003 
 
Diana Robins 
Department of Psychology 
University of Connecticut 
406 Babbidge Road, U-1020 
Storrs, Connecticut 06269-1020 
 
Dear Dr. Robins: 
I am a doctoral candidate in the Human Development and Family Science at Oklahoma 
State University. My dissertation research focuses on the early identification of children 
who have Fragile X Syndrome. I am particularly interested in contributing to the 
epidemiological database regarding developmental disabilities in infants and toddlers. 
The need is immense for heightened awareness of Fragile X Syndrome and pivotal early 
interventions. As the parent of two boys who have Fragile X Syndrome (full-mutation) 
and as a behavioral health professional, I feel impelled to contribute significantly to the 
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knowledge base regarding this complex and intriguing disorder as well as other 
associated developmental disabilities.  
 
I recently read your (2001) article, the Modified checklist for autism in toddlers: An 
initial Study investigating the early detection of autism and pervasive developmental 
disorders. Journal of Autism and Developmental Disorders, 31(2), 131-144. I would 
greatly appreciate an opportunity to review your questionnaire and request your 
permission to use it as a measure in my dissertation research study.  
 
I have enclosed a copy of an abstract of my proposed research. I would appreciate your 
assistance immensely and I look forward to your reply. 
 
Sincerely,  
 
 
Vanessa J. Thomas, Ph.D. (C)  MS, RN 
Human Development and Family Science 
Oklahoma State University 
 
522 East Newton Place 
Tulsa, Oklahoma 74106 
E-mail address: tveness@okstate.edu 
Telephone:(918)295-7858 
Enclosures 
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APPENDIX I 
 
M-CHAT 
 
Please fill out the following about how your child usually is. Please try to answer every question. If the 
behavior is rare (e.g. you've seen it once or twice), please answer as if the child does not do it. 
 
1.  Does your child enjoy being swung, bounced on your knee, etc.?    Yes No 
2.  Does your child take an interest in other children?       Yes No 
3.  Does your child like climbing on things, such as up stairs?      Yes No 
4.  Does your child enjoy playing peek-a-boo/hide-and-seek?      Yes No 
5.  Does your child ever pretend, for example, to talk on the phone or take care of dolls, 
     or pretend other things?        Yes No 
6.  Does your child ever use his/her index finger to point, to ask for something?    Yes No 
7.  Does your child ever use his/her index finger to point, to indicate interest in something?  Yes No 
8.  Can your child play properly with small toys (e.g. cars or bricks) without just                Yes No 
     mouthing, fiddling, or dropping them? 
9.  Does your child ever bring objects over to you (parent) to show you something?   Yes No 
10. Does your child look you in the eye for more than a second or two?    Yes No 
11. Does your child ever seem oversensitive to noise? (e.g., plugging ears)    Yes No 
12. Does your child smile in response to your face or your smile?     Yes No 
13. Does your child imitate you? (e.g., you make a face-will your child imitate it?)   Yes No 
14. Does your child respond to his/her name when you call?      Yes No 
15. If you point at a toy across the room, does your child look at it?     Yes No 
16. Does your child walk?         Yes No 
17. Does your child look at things you are looking at?      Yes No 
18. Does your child make unusual finger movements near his/her face?     Yes No 
19. Does your child try to attract your attention to his/her own activity?    Yes No 
20. Have you ever wondered if your child is deaf?       Yes No 
21. Does your child understand what people say?       Yes No 
22. Does your child sometimes stare at nothing or wander with no purpose?    Yes No 
23. Does your child look at your face to check your reaction when faced with    Yes No 
      something unfamiliar? 
 
 
1999 Diana Robins, Deborah Fein, & Marianne Barton 
Please refer to: Robins, D., Fein, D., Barton, M., & Green, J. (2001). The Modified Checklist for Autism in 
Toddlers: An initial study investigating the early detection of autism and pervasive developmental 
disorders. Journal of Autism and Developmental Disorders, 31 (2), 131-144. 
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APPENDIX J 
 
January 24, 2004 
 
Dear Parent / Primary Caregiver: 
I am Vanessa Johnson Thomas, Mom to John, 14 (DD; Sammy, 13 (DD) and Elizabeth, 19 yrs (typically 
developing). I am also a doctoral candidate in the Human Development and Family Science Program at 
Oklahoma State University. My dissertation advisors, Dr. Patricia Self, and I have are particularly 
interested in identifying infants and toddlers who may need early interventions. As the parent of two boys 
who have significant development disabilities and as a health professional, I feel driven to help, by doing 
research. The purpose of our research is to gather information that may help children to receive important 
help earlier. Research is a major step toward successful treatments.   
 
We invite you to complete surveys online if one or more of your children are between the ages of 12 
months to 18 years of age and have received a diagnosis by a health care professional of either: 
 
No disabilities   
Autism 
Down Syndrome 
Fragile X Syndrome 
Fragile X Premutation Carrier 
Asperger Syndrome 
Pervasive Developmental Disorder (PDD-NOS) 
 
If you want to help with our study, please click  http://langston.osu-tulsa.okstate.edu/vthomas  to go to the 
website in which English and Spanish versions of the surveys are available The English version is the 
default language. The “start survey” link at the bottom of the “How to Participate” page leads to the first 
survey. It takes about 15 minutes to finish all of the surveys online. We would appreciate your help and will 
send a report of the results of the study to moderators, list servs and message boards, clinics, etc. after we 
finish the study.  
 
All information that you give will be kept 100% private. We will not collect ANY identifying information 
and will have no way of knowing who filled-out the surveys. Your help is important! We hope our research 
will increase awareness, research and early interventions with children.  
 
Vanessa Johnson Thomas, Ph.D., (candidate), MS, RN, BC 
Oklahoma State University Human Development and Family Science 
700 N. Greenwood  NCB 358 
Tulsa, Oklahoma 74106 
(918) 594-8082 (Office) 
tveness@okstate.edu 
 
Patricia Self, Ph.D., Professor 
Oklahoma State University 
Human Development and Family Sciences 
HES RM 226A 
Stillwater, Oklahoma 74078 
(405) 744-8348 (Office) 
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APPENDIX K 
 
Sample Website Pages 
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APPENDIX L 
 
Rationale for Internet Data Collection Method 
 
Internet 
The Internet has become an important communication tool in modern society 
(Frankel & Sanyin, 1999). Potentially, the Internet may change the way we conduct 
scholarly research (Harris & Dersch, 1999). The Internet can be very beneficial in the 
areas of participant recruitment and data collection. Internet sites that house 
questionnaires or other forms of survey instruments are not significantly different from 
other research involving questionnaires. Researchers to ensure results that are both 
reliable and valid must adhere to specific guidelines and protocols. Despite the 
similarities between traditional (pen and paper) and Internet conducted research, there are 
differences that must be addressed (Harris & Dersch, 1999).        
World Wide Web (WWW) technology is affording opportunities for research 
never before possible. For instance, a study of cholangiocarcinoma, a rare cancer of the 
bile ducts, was possible when a computerized disease tracing system was developed that 
could then access a database using the Web. Data were gathered from patients diagnosed 
with cholangiocarcinoma at the Mayo Clinic and Foundation outpatient clinics and 
hospitals. Permission was obtained from the institutional review board, the security 
committee, the clinical practice committee, and the legal department (de Groen, Barry, & 
Schaller, 1998).   
There are many benefits of conducting research online including data collection 
from widely dispersed populations with lower cost (Frankel & Sanyin, 1999). Internet 
research may provide certain individuals or populations with the opportunity to be 
involved in research of which they may otherwise be unaware. According to Currie 
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(1999), recruiting subjects from the web is no different than soliciting using consumer 
groups’ newsletters. Subject recruitment via the Internet is bound by the same ethical 
principles that bind conventional subject recruitment.   
Lenert et al. (2002) tested the validity of data collected via the Internet by 
conducting a study to determine if subjects who participated in migraine research on the 
Internet actually had the disorder. The subjects were screened using various methods 
including a comparison of their reported symptoms with the International Headache 
Society’s criteria for diagnosis of migraines. Of the 45 participants who consented for 
physician verification of their Internet-derived diagnosis, 44 (97.6%) were confirmed by 
their physicians, and one had another primary diagnosis of cluster headaches. Lenert et al. 
(2002) concluded, “the validity of self-reported diagnosis of migraine does not appear to 
be an obstacle to conduction research in subject populations on the Internet” (p. 200). 
Although there are many advantages to conducting Internet research, there are 
ethical and scientific concerns as well (Currie, 1999). Internet researchers must address 
potential breaches of privacy and confidentiality related to technology in order to 
minimize any potential risks (Frankel & Sanyin, 1999). Raw data cannot be locked in a 
file cabinet when conducting Internet research, so ensuring data is encrypted and behind 
firewalls is essential (Lutz & Henkind, 2000). In addition, participants need to know how 
the information they are providing will be used both now and in the future. 
Informed consent has also been a topic that needs special consideration. 
Safeguards need to be built in that would ensure the participant fully understands what 
they have read. For example, Lutz, and Henkind suggest asking participants to read 
pertinent information about the study and be quizzed afterward. In addition, Currie 
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(1999), suggests giving potential participants the opportunity to ask the researcher 
questions via interactive e-mail or telephone contact. One drawback of Internet research 
in general is that it excludes anyone who does not have Internet access. For people with 
few economic resources this can be a barrier to their participation (Harris & Dersch, 
1999). 
Although Internet research is creating some exciting opportunities for scientific 
research, it is not without potential problems. Internet recruitment and data collection are 
becoming well accepted and researchers must be willing to educate themselves regarding 
the above-mentioned unique differences inherent to Internet research so reliability and 
validity can be maintained.  
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